

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The "Well-being paradox" revisited: Quality of life and psychosocial long-term outcomes in over 4,000 adults with congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049531
Article Type:	Original research
Date Submitted by the Author:	28-Jan-2021
Complete List of Authors:	Andonian, Caroline; German Heart Centre Munich, Freilinger, Sebastian; German Heart Centre Munich, Achenbach, Stephan; University of Erlangen, Cardiology Ewert, Peter; German Heart Centre, Paediatric Cardiology Grundlach, Ulrike; University of Erlangen, Cardiology Hoerer, Jürgen; Deutsches Herzzentrum München, Cardiac Surgery Kaemmerer, Harald Pieper, Lars; Technische Universität Dresden, Behavioural Epidemiology Weyand, Michael; University of Erlangen, Department of Cardiothoracic surgery Neidenbach, Rhoia ; Deutsches Herzzentrum Munchen Beckmann, Jürgen; Technische Universität München, Sport- and Health Sciences
Keywords:	Adult cardiology < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The "Well-being paradox" revisited: Quality of life and psychosocial long-term outcomes in over 4,000 adults with congenital heart disease

Caroline Andonian^{1,2}, Sebastian Freilinger¹, S. Achenbach³, Peter Ewert¹, U. Gundlach³, Jürgen Hörer⁴, Harald Kaemmerer¹, Lars Pieper⁵, Michael Weyand⁶, Rhoia Clara Neidenbach^{1*}, Jürgen Beckmann^{2,7,8*}

¹ Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Germany

² Department of Sport and Health Sciences, Chair of Sport Psychology, Technical University Munich, Germany

³ Department of Cardiology, University of Erlangen, Erlangen, Germany

⁴ Department for Congenital and Pediatric Heart Surgery, German Heart Center Munich, Technical University Munich, Germany, Division for Congenital and Pediatric Heart Surgery, University Hospital Großhadern, Ludwig-Maximilians University, Munich, Germany

⁵ Department of Behavioral Epidemiology, Technical University of Dresden, Germany

⁶ Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany

⁷ School of Human Movement and Nutrition Sciences, University of Queensland, Australia

⁸ Health Research Institute, University of Limerick, Ireland

* The last two authors contributed as last authors.

Correspondence to: Caroline Andonian, M.Sc., M.Sc., Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Germany, Email: andonian@dhm.mhn.de

Abstract

Objective: The present cross-sectional study investigated quality of life (QOL) in a large cohort of German adults with congenital heart disease (ACHD) in association with sociodemographic and clinical variables.

Methods: Patient reported outcome measures on demographic and clinical variables were retrospectively analysed in a representative sample of 4,015 adults with various forms of CHD (41.8 ± 17.2 years; 46.5% female). QOL was assessed using the EQ-5D-5L. Associations of QOL with patient reported clinical and sociodemographic variables were quantified using multiple regression analysis and multiple ordinal logit models.

Results: Overall, ACHD patients reported a good QOL comparable to German population norms. The most frequently reported complaints occurred in the dimensions pain/discomfort and anxiety/depression. QOL differed significantly within ACHD subgroups, with patients affected by pre-tricuspid shunt lesions indicating the most significant impairments. Older age, female sex, medication intake and the presence of comorbidities, were associated with significant reductions in QOL. CHD severity was positively associated with QOL.

Conclusion: Current findings temper widely held assumptions among clinicians and confirm that ACHD experience a generally good QOL. However, specific subgroups may require additional support to cope with disease-related challenges. The negative correlation of QOL with age is especially alarming as the population of ACHD is expected to grow older in the future.

Keywords: adults with congenital heart disease; psychological situation; quality of life; prevention; EQ5D

1 **Strengths and Limitations**

- 2 • First study of its kind exploring quality of life (QOL) among 4,015 patients with different
3 medical and sociodemographic backgrounds.
- 4 • Uniform conceptualization of QOL based on EQ-5D-5L, which is a highly reliable and valid
5 outcome measure within the cardiovascular area.
- 6 • Present findings help clinicians to identify specific subsets of patients who require extra
7 psychological support and therefore constitute a major step in paving the way towards
8 integrative cardiac care.
- 9 • Causal inferences are not possible due to the cross-sectional design of this study.
- 10 • Ambiguous findings open new avenues for future research in understanding the construction of
11 self-rated health despite or as a consequence of CHD.

1 Introduction

2 Although most patients with congenital heart disease (CHD) survive into adulthood, many of them are
3 not cured and need to adapt to their chronic medical condition throughout their lives [1]. Besides
4 symptoms related to their heart disease, lifelong psychosocial impairments may seriously impact the
5 patients' perceived quality of life (QOL) [2]. While clinical research traditionally focused on objective
6 medical outcomes, the relevance of QOL is increasingly recognized in the evaluation of care for adults
7 with congenital heart disease (ACHD) [3].

8 Research on QOL in ACHD is still relatively scarce and not conclusive. Empirical findings indicate that
9 QOL among ACHD is compromised by sociodemographic factors (unemployment, older age, single
10 status), psychological features (negative illness perceptions, distressed personality) and medical
11 characteristics (e.g. hospitalization, worse functional status). QOL has been found to be positively
12 associated with higher socioeconomic and educational status, stronger social support, better functional
13 class, better knowledge of CHD, stronger sense of coherence as well as the absence of cardiac surgery.
14 Existing findings are inconsistent regarding cardiovascular status, medication, age, and gender, although
15 these variables appeared to be the most frequently investigated determinants [4].

16 These inconsistent results of existing research on QOL in ACHD can be attributed to a lack of a clear
17 conceptual background, inconsistent methods and insufficient sample sizes [4]. Additionally, the high
18 heterogeneity of ACHD constitutes a substantial confounding factor due to their great anatomical and
19 clinical disease complexity. Most studies on QOL in ACHD focused on specific subgroups of patients
20 which limits their informational value. Consequently, clinical parameters were not sufficiently examined
21 to explain potential differences in QOL by the underlying diagnosis or severity of CHD. Although a
22 recent review attests temporal qualitative improvements in QOL studies over the last decades, the
23 current research situation still fails to meet scientific quality criteria [5].

24 The present study aimed to assess QOL within a large sample of ACHD in Germany and examine
25 potential determinants of QOL in terms of patient reported sociodemographic and medical
26 characteristics. Identifying determinants of QOL along with special needs of ACHD could advance the
27 improvement of health care for this growing patient population.

28 Methods

29 Population

30 The study was conducted at the Dpt. of Congenital Heart Disease and Pediatric Cardiology at the
31 German Heart Center Munich, Technical University Munich, under the approval of the Ethics
32 Committee of the contributing centers (TU Munich 157/16S). Guidelines on good clinical practice and
33 data protection guidelines were followed. As part of the ongoing cross-sectional VEMAH research

1 project (engl. "Medical Care Situation of ACHD") it constitutes the largest ever attempt to
2 comprehensively assess the health care situation of ACHD in Germany. Inclusion criteria were: (1)
3 confirmed diagnosis of CHD, (2) participant age 18 years and older, (3) necessary physical, cognitive
4 and language capabilities to complete self-report questionnaires, (4) German speaking. No patients were
5 asked for input in the creation of this research.

6 **Measures**

7 Patients completed a questionnaire either in person, online or by mail to maximize response. Data
8 collection took place between 2016 and 2019. QOL was measured using the generic questionnaire EQ-
9 5D-5L[6].

10 I. *Demographic and clinical information*

11 Sociodemographic and medical information was obtained by a self-devised questionnaire. Medical
12 variables included leading CHD, medication, presence of cyanosis, (non-) cardiac comorbidities and
13 hereditary diseases. Following the recommendations of the American College of Cardiology, patients
14 were divided into three severity groups based on their CHD diagnosis (ACC) [7].

15 II. *Quality of Life (EQ-5D-5L)*

16 QOL was measured using the updated five-level version of the EQ-5D [6] which provides a simple,
17 generic measure of a patient's perceived health status. The EQ-5D-5L consists of a descriptive system
18 questionnaire and a visual analogue scale (VAS). The descriptive system comprises five dimensions:
19 mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each patient was asked to
20 indicate his perceived impairments on a 5-point Likert scale ranging from "no problems" to "extreme
21 problems/unable". Responses were converted into a single weighted index score (EQ-5D index) which
22 indicates how good or poor the respondent's health status is based on existing population norms. A value
23 set for the EQ-5D-5L, based on a representative sample of the German population, has recently been
24 developed [8]. The VAS indicates a patient's overall health state on the day of the questionnaire
25 completion. It is a scale which ranges from 0 ("The worst health you can imagine") to 100 ("The best
26 health you can imagine") and provides a quantitative measure of a patient's perceived health. The EQ-
27 5D-5L proved to be a reliable and valid method for measuring QOL in cardiovascular populations
28 (Cronbach's alpha = 0.856) [9].

29 **Statistical analysis**

30 Statistical analysis was performed using IBM SPSS Statistics 24.0 (IBM, Armond, New York, United
31 States). Descriptive measures were calculated for sample characteristics, including patient reported
32 sociodemographic and medical variables (absolute and relative frequencies, mean and standard
33 deviations). The relationships between CHD diagnosis groups and EQ-5D-index values, including the
34 underlying dimensions mobility, self-care, usual activities, pain/discomfort and anxiety/depression were

1 analysed. The comparison of ordinal scaled values was based on cumulative frequencies representing
2 the relative proportion of patients with moderate to severe symptoms on the specific dimensions.
3 Kruskal-Wallis-tests were applied to reveal significant differences between EQ-5D-dimensions and
4 metric index values. Furthermore, the relationship between both EQ-5D VAS scores and dedicated index
5 values was analysed with respect to various patient characteristics. Multiple regression models using
6 Ordinary least squares (OLS)-estimates were calculated, while bivariate Pearson-coefficients were used
7 to analyse the correlation between VAS and index scores. Finally, multiple ordinal logit models were
8 applied to identify significant predictors of the respective QOL dimensions.

9 **Patient and Public Involvement**

10 Neither patients nor the public were involved in the design and conduct of this research. The
11 methodology of this research was adapted in multidisciplinary collaboration.

12 **Results**

13 **Sample characteristics**

14 A total of 4,015 patients was analysed (46.5% female) (**Table 1**). The mean age of ACHD was $41.8 \pm$
15 17.2 [18-97] years. Patients were subclassified according to the underlying CHD into six main groups,
16 consisting of complex CHD (n=581); pre-tricuspid shunts (n=621); post-tricuspid shunts (n=406); right
17 heart or pulmonary artery anomalies (n=526); left heart or aortic anomalies (n=898); and miscellaneous
18 CHD (n=602). 15.4 % of patients (n=602) presented with cyanosis. The severity of CHD was determined
19 according to the Warnes classification system as simple (n=1,722, 62.0%), intermediate (n=650, 23.4%)
20 or severe (n=406, 14.6%) [10].

21 **QOL and ACHD**

22 EQ-5D dimensions were found to be differently associated with CHD subgroups. Significant differences
23 between the underlying diagnosis were found on all dimensions ($p < .001$). Compared to all other
24 subgroups, pre-tricuspid shunts were particularly impaired in mobility, daily activities, pain/discomfort
25 and anxiety/depression (**Table 2**). In contrast, complex CHD showed the least problems on the respective
26 descriptive dimensions (**Figure 1-5**).

27 Similar results were reflected by EQ-5D VAS and index values ($p < .001$) with EQ-5D VAS values being
28 highest in patients with right heart/pulmonary artery anomalies and complex CHD and lowest in patients
29 with pre-tricuspid shunts. Observed differences were less extreme between descriptive EQ-5D index
30 values. Both EQ-5D values were positively correlated ($r = .623$, $p < .001$), with coefficients being the
31 lowest for patients with complex CHD ($r = .579$, $p < .001$) and highest for patients with left heart/aortic
32 anomalies ($r = .653$, $p < .001$). Variations in QOL were observed depending on the type of measurement

1 which was applied. Accordingly, the mean VAS score displayed a significantly lower QOL than the
2 descriptive EQ-5D index value.

3 **Socioeconomic Determinants of QOL**

4 OLS-Regression models were applied to analyse relationships of sociodemographic variables with EQ-
5 5D VAS and index values (**Table 3**). At the 5% level of significance, age had the highest negative impact
6 on VAS values ($\beta=-.32$) and Index values ($\beta=-.22$). Thus, QOL decreased with advancing age. Patients
7 aged 65+ years indicated the lowest values on both scales. Means for both EQ-values were slightly
8 higher in male than in female patients. Medication intake had significant negative effects on QOL in
9 both measures. Model fit was slightly higher for the dependent variable in VAS values ($R^2=.190$) than
10 EQ-5D index values ($R^2=.112$).

11 **Clinical Determinants of QOL**

12 EQ-5D-dimensions were analysed more specifically in regard to different medical features such as
13 connective tissue disease diseases with cardiovascular involvement, cyanotic status and severity codes
14 of CHD. Several ordered logistic regression models were applied using each of the five dimensions as
15 dependent variables (**Table 4**). Generally, patients with comorbidities had significantly increased odds
16 of reporting problems on all dimensions than patients without comorbidities ($p<.05$). Non-cardiac
17 comorbidities accounted for significantly higher odds of having problems than cardiac comorbidities.
18 No significant effects could be observed for cyanotic status. Furthermore, regression models showed no
19 effects for patients with simple or moderate disease severity classes. It is remarkable that severely
20 classified patients indicated decreased odds of suffering from issues related to mobility or self-care than
21 patients in lower Warnes' classes.

22 **Discussion**

23 QOL is one of the most important measures used to assess the psychosocial impact of chronic disease
24 on a patient's life. This is the first study to investigate patient reported QOL within a cohort of 4,015
25 patients encompassing a broad spectrum of CHD. QOL in ACHD was assessed by utilizing the EQ-5D-
26 5L, a highly reliable and valid outcome measure within the cardiovascular area [11]. It comprises
27 two types of measurement and therefore provides a global view on QOL in terms of general life
28 satisfaction. This allowed to reveal genuine differences in QOL among patients with different medical
29 and sociodemographic backgrounds, regardless of methodological considerations. Within the context of
30 this study, QOL quantifies the influence of CHD on a patient's ability to function and derive personal
31 satisfaction from life.

1 QOL in ACHD

2 In line with previous findings [12], ACHD in general reported a good level of wellbeing which is
3 comparable to German population norms [13]. The two-fold measure of QOL revealed that the type of
4 measurement affects QOL scores differently. Apparently, the overall VAS score indicated a significantly
5 lower QOL than the descriptive EQ-5D index value. One explanation for this discrepancy are differences
6 in the QOL coverage of both measures. It can be assumed that the descriptive system encourages a
7 patient to examine QOL from various angles as the system breaks down QOL into various components.
8 Thus, QOL is regarded as a subjective concept being influenced by multiple causal factors [14]. In
9 contrast, VAS picks up a one-dimensional view of perceived health where patients may indicate a higher
10 occurrence of problems by focusing on somatic health restrictions imposed by their CHD. When
11 comparing the quantitative association of CHD with QOL to other chronic disorders, the average
12 reduction in VAS values in the current sample roughly resembles observations of various other heart
13 diseases [13]. In line with previous research, patients most frequently reported problems in the areas of
14 pain/discomfort (16.3%) and anxiety/depression (14.3%) [15]. These rates lie considerably above
15 German population standards, which document symptoms of anxiety/depression in 4.7% of the general
16 public. This result further supports previous research showing that ACHD are specifically prone to
17 increased psychological distress and therefore require additional psychosocial support [16].

18 A closer look at different diagnosis groups reveals, that patients with pre-tricuspid shunts were
19 particularly impaired in QOL. Comparable data have previously documented that QOL is not necessarily
20 congruent with the complexity or severity of a heart disease. Even mild primary pre-tricuspid shunts can
21 have a considerable negative impact on QOL [17]. Clinical reality shows that pre-tricuspid shunts are
22 often detected incidentally and later in life creating a different psychological situation than diagnosis of
23 CHD early in life. Children, who grew up with the awareness of their CHD, may acquire a greater sense
24 of appreciation for life and expectations consistent with their capabilities and limitations [18]. From a
25 life-stage perspective, adult developmental tasks may be disrupted by a sudden diagnosis of CHD and
26 patients may experience the effects of their CHD more negatively leading to higher emotional distress.
27 Life-stage variables, such as age at diagnosis or years of survival, need to be further investigated as
28 possible determinants of QOL.

29 Socioeconomic determinants of QOL

30 Despite good overall QOL, EQ-5D index and VAS values deteriorated with increasing age. This might
31 be explained by the uncertainty in disease prognosis manifesting itself in an increased sense of
32 vulnerability in this patient group [19]. Most patients with CHD are known to do well in the first decades
33 of life until they eventually develop unexpected age and disease-related comorbidities. This
34 development deserves special attention as the group of ACHD is expected to grow steadily in the future
35 [1].

1
2
3
4 1 In contrast to previous findings [12], the present study revealed modest gender-related differences in
5 2 QOL. Females were more likely to report poor QOL than males. These findings may be attributed to
6 3 psychosocial factors rather than gender per se [20]. In general, gender is found to influence health
7 4 expectations, health behaviours and perceived health outcomes [21]. Females may face a triple burden
8 5 shouldering family responsibility, professional ambition and demands of their chronic disease. Research
9 6 has demonstrated that females were less likely to return to work, more likely to decline psychological
10 7 counselling and more socially isolated than males [22]. It has also been argued that females were more
11 8 willing to disclose problems than males concerning their QOL, which may partly explain the difference
12 9 in their QOL [21]. Engelfriet et al. (2005) also showed that females with CHD were more often
13 10 symptomatic and presented functional impairments, despite a higher overall mortality in males over a
14 11 5-year period [23]. Gender disparities in patient-provider communication and dissatisfaction with health
15 12 care might be another reason for decreased QOL in females. They might have higher expectations and
16 13 a stronger demand for more participatory encounters with their healthcare providers [20]. Improved
17 14 recognition and understanding of these gender-specific differences and challenges among ACHD is vital
18 15 to improve their cardiovascular health over the long-term.

19 16 Reported medication intake was inversely associated with QOL in the present study This appears
20 17 plausible because extensive or inappropriate medication can lead to severe side effects and even higher
21 18 morbidity which may considerably impair QOL [24]. Aside from incorrect pharmaceutical treatment,
22 19 the daily intake of medication is a constant reminder of illness and may have a negative impact on life
23 20 satisfaction. Consequently, medication may either be a facilitator by providing new opportunities or an
24 21 intensifier of problems by adverse psychological and somatic side effects.

22 **Clinical determinants of QOL**

23 23 Despite all advances in cardiac care, many CHD patients are left with significant residua, sequels or
24 24 complications from the underlying anomaly [7, 25]. The impact of comorbidities in ACHD is largely
25 25 underestimated [26]. The current study indicates that the presence of comorbidities increases the risk of
26 26 problems on all dimensions of the EQ-5D. It is conceivable that affected patients report a lower health
27 27 status since they may experience serious restrictions in various life domains. As comorbidities become
28 28 increasingly dominant with advancing age, they may also explain the recorded deterioration of QOL
29 29 with age in the present sample.

30 30 It is remarkable that patients with a more complex CHD scored significantly better in QOL domains.
31 31 Until now, research has failed to demonstrate a clear-cut correlation between disease complexity and
32 32 QOL [4]. Although the present finding may seem counterintuitive at first, there are various possible
33 33 explanations for a better QOL in the light of a chronic condition. Keyes' two continua model of mental
34 34 health [27] provides an important framework for explaining why patients might experience a good QOL
35 35 despite their CHD. Accordingly, mental health is a complex state resulting from an interplay of
36 36 environmental and psychological factors that have a profound influence on one's subjective wellbeing.

1
2
3
4 1 Keyes' model holds that mental health (sometimes referred to as mental wellbeing) and mental illness
5 2 are orthogonally related phenomena and not two endpoints of one single continuum. Although the
6 3 current state of research confirms elevated levels of mental illness among ACHD [16], this does not
7 4 necessarily imply impaired mental wellbeing or decreased QOL among these patients. Furthermore, the
8 5 disability paradox explains why individuals may perceive a high QOL despite serious limitations.
9 6 Accordingly, QOL depends upon finding a balance in life and maintaining harmonious social
10 7 relationships [28]. The characteristics associated with a severe CHD may potentially include favourable
11 8 and compromising factors and thus explain both extremes of QOL in ACHD. Lastly, growing up with a
12 9 CHD can lead to a so-called "response shift" in terms of redefining priorities in one's life [29]. It is
13 10 perceivable that patients develop different values from those of healthy persons in the face of a life-
14 11 threatening, chronic illness. In this context, Sprangers et. al (1999) proposed a theoretical model to
15 12 clarify and predict changes in QOL as a result of various dispositional characteristics, a patient's health
16 13 status and mechanisms to accommodate to these changes [30].

17 14 Despite the extensive power of the present study, current results should be interpreted with caution due
18 15 to certain limitations. The study was retrospective and cross-sectional in nature and does not allow to
19 16 disentangle any conclusions about the directionality of effects or the development of QOL over time.
20 17 Since all information was based on patient-reported outcomes, medical data may have been classified
21 18 incorrectly due to a patient's limited knowledge of his or her condition. Consequently, surgical status of
22 19 patients could not be identified. Subsequently, it would be advisable to synchronize these data with
23 20 medical records in order to disentangle the effects of empirical-medical observations on QOL. As the
24 21 enrolment was voluntary, selection bias could not be excluded and may hamper representativeness.
25 22 Further, this study was performed at a tertiary care center for ACHD which does not reflect the typical
26 23 population of CHD. The presented data derive solely from patients living in Germany. Generalization
27 24 of the conclusions and transmission to patients living in other countries or different ethnical groups is
28 25 debatable. Nonetheless, the obtained results reflect a wide variety of CHD and could therefore be a
29 26 foundation for diagnosis-specific interventions. Finally, no control group was involved, and data could
30 27 only be compared to published national EQ-5D studies.

28 **Conclusion**

29 29 The present study shows that ACHD experience – on aggregate – a good QOL which is indistinguishable
30 30 from healthy individuals. Against expectation, patients with complex CHD scored higher on QOL.
31 31 However, specific subgroups of patients indicate significant reductions in QOL and may require extra
32 32 support in their care to cope with challenges associated with their underlying CHD. The negative
33 33 correlation with age deserves particular attention as it could lead to a decrease in QOL with the growing
34 34 median age of this patient population.

1 QOL is regarded as a central target in the treatment of chronically ill patients. This study supports the
2 need to further assess and promote mental wellbeing in ACHD to safeguard surgical successes of the
3 past decades which have ensured the survival of CHD patients into adulthood. Successful treatment
4 implies not only an increased length of survival but also enhanced subjective wellbeing and QOL.

5 **Declarations**

6 **Funding:** This work was supported by the German Heart Foundation (“Deutsche Herzstiftung e.V.”)
7 (grant number F-30-15), the patient organization “Herzkind e. V.”, Actelion Pharmaceuticals Germany
8 GmbH (grant number MED-2015-495) and the German health care insurance AOK-Bayern

9 **Competing Interest:** The authors have no conflicts of interest to declare.

10 **Ethics Approval:** The study was part of the nationwide VEMAH project which was approved on
11 04/05/2016 by the ethical committee of the Technical University of Munich (157/16S).

12 **Consent to participate:** Informed consent was obtained from all individual participants included in the
13 study.

14 **Consent for publication:** All authors consent to the publication of the manuscript in the Journal
15 “Clinical Research in Cardiology”.

16 **Availability of data and material:** The datasets generated during and/or analysed during the current
17 study are available from the corresponding author on reasonable request.

18 **Author Contributions:**

19 (1) *Conception and design:* CA, SF, HK, LP, RN, JB

20 (2) *Administrative support:* All authors

21 (3) *Collection and assembly of data:* CA, SF, SA, UG, LP, MW, RN

22 (4) *Data analysis and interpretation:* CA; SF, LP, JB

23 (5) *Manuscript writing:* CA, RN, JB

24 (6) *Final approval of manuscript:* All authors.

1 References

1. Zimmerman MS, Smith AGC, Sable CA, Echko MM, Wilner LB, Olsen HE, et al. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Child Adolescent Health*. 2020;4(3):185-200.
2. Kovacs AH, Sears SF, Saidi ASJAhj. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. 2005;150(2):193-201.
3. Hunter AL, Swan L. Quality of life in adults living with congenital heart disease: beyond morbidity and mortality. *Journal of thoracic disease*. 2016;8(12):E1632.
4. Moons P, Luyckx K. Quality-of-life research in adult patients with congenital heart disease: current status and the way forward. *J Acta Paediatrica*. 2019;108(10):1765-72.
5. Bratt E-L, Moons P. Forty years of quality-of-life research in congenital heart disease: Temporal trends in conceptual and methodological rigor. *International journal of cardiology*. 2015;195:1-6.
6. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *J Quality of life research*. 2011;20(10):1727-36.
7. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2018:CIR. 0000000000000603.
8. Grochtdreis T, Dams J, König H-H, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. *J The European Journal of Health Economics*. 2019;20(6):933-44.
9. Boczor S, Daubmann A, Eisele M, Blozik E, Scherer M. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L™. *J BMC public health*. 2019;19(1):1464.
10. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI, et al. Task force 1: the changing profile of congenital heart disease in adult life. 2001;37(5):1170-5.
11. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. *Health quality of life outcomes*. 2010;8(1):13.
12. Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, et al. Quality of life of adults with congenital heart disease in 15 countries: evaluating country-specific characteristics. *Journal of the American College of Cardiology*. 2016;67(19):2237-45.
13. Huber MB, Reitmeir P, Vogelmann M, Leidl R. EQ-5D-5L in the general German population: comparison and evaluation of three yearly cross-section surveys. *International journal of environmental research public health*. 2016;13(3):343.
14. Moons P, Deyk KV, Bleser LD, Marquet K, Raes E, Geest SD, et al. Quality of life and health status in adults with congenital heart disease: a direct comparison with healthy counterparts. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2006;13(3):407-13.
15. Berghammer M, Karlsson J, Ekman I, Eriksson P, Dellborg M. Self-reported health status (EQ-5D) in adults with congenital heart disease. *J International journal of cardiology*. 2013;165(3):537-43.
16. Andonian C, Beckmann J, Biber S, Ewert P, Freilinger S, Kaemmerer H, et al. Current research status on the psychological situation of adults with congenital heart disease. 2018;8(6):799.

17. Vigl M, Niggemeyer E, Hager A, Schwedler G, Kropf S, Bauer U. The importance of socio-demographic factors for the quality of life of adults with congenital heart disease. *Quality of Life Research*. 2011;20(2):169-77.
18. Moons P, Norekvål TM. Is sense of coherence a pathway for improving the quality of life of patients who grow up with chronic diseases? A hypothesis. *J European Journal of Cardiovascular Nursing*. 2006;5(1):16-20.
19. Saliba Z, Butera G, Bonnet D, Bonhoeffer P, Villain E, Kachaner J, et al. Quality of life and perceived health status in surviving adults with univentricular heart. *J Heart*. 2001;86(1):69-73.
20. Chen C-A, Liao S-C, Wang J-K, Chang C-I, Chiu S, Chen Y-S, et al. Quality of life in adults with congenital heart disease: biopsychosocial determinants and sex-related differences. *Heart*. 2011;97(1):38-43.
21. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. *Journal of general internal medicine*. 2001;16(4):266-75.
22. Ford ES, Mokdad AH, Li C, McGuire LC, Strine TW, Okoro CA, et al. Gender differences in coronary heart disease and health-related quality of life: findings from 10 states from the 2004 behavioral risk factor surveillance system. *J Journal of Women's Health*. 2008;17(5):757-68.
23. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilén U, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period: the Euro Heart Survey on adult congenital heart disease. *J European heart journal*. 2005;26(21):2325-33.
24. Olsson IN, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. *J Health quality of life outcomes*. 2011;9(1):95.
25. Perloff JK, Warnes CA. Challenges posed by adults with repaired congenital heart disease. *Circulation*. 2001;103(21):2637-43.
26. Neidenbach RC, Lummert E, Vigl M, Zachoal R, Fischereder M, Engelhardt A, et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovascular Diagnosis and Therapy*. 2018.
27. Keyes CL. The mental health continuum: From languishing to flourishing in life. *J Journal of health social behavior*. 2002:207-22.
28. Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. *Social science & medicine*. 1999;48(8):977-88.
29. Rapkin BD, Schwartz CE. Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift. *Health and quality of life outcomes*. 2004;2(1):14.
30. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. *J Social science medicine*. 1999;48(11):1507-15.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Characteristics of the underlying study population.

Variables	n (%)
Age group (n=3,903)	
18-34	1,663 (42.6)
35-64	1,733 (44.4)
65+	507 (13.0)
Gender (n=3,898)	
male	2,087 (53.5)
female	1,811 (46.5)
Residence (n=3,855)	
City	775 (20.1)
Town	590 (15.3)
Rural	2,490 (64.6)
Insurance (n=3,905)	
Public	3,679 (94.2)
Private	219 (5.6)
No Insurance	7 (.2)
Type of CHD (n=4,015)	
Complex Congenital Heart Defects	581 (14.5)
Primary Pre-Tricuspid Shunts	621 (15.5)
Primary post-Tricuspid Shunts	406 (10.1)
Right Heart / Pulmonary artery anomalies	526 (13.1)
Left Heart / Aortic anomalies	898 (22.4)
Miscellaneous CHD	602 (15.0)
Unclassifiable	380 (9.5)
Warnes Class (n=2,778)	
Simple	1,722 (62.0)
Moderate	650 (23.4)
Severe	406 (14.6)

Table 2. Leading diagnosis of CHD and EQ-5D-results.

EQ-5D	Total	Complex Congenital Heart Defects	Primary pre- tricuspid shunts	Primary post- tricuspid shunts	Right Heart / pulmonary artery anomalies	Left Heart / aortic anomalies	Unclassifiable	Miscellaneous	p-Value
Dimension	n=4,014	n=581	n=621	n=406	n=526	n=898	n=380	n=602	
Mobility	12.2	8.6	13.6	10.4	9.6	10.5	15.0	16.6	<.001*
Self-Care	3.5	2.0	3.0	2.3	3.2	3.5	4.4	5.4	.017*
Usual activities	13.2	13.7	13.5	11.2	12.6	11.1	14.1	16.8	<.001*
Pain/Discomfort	16.3	13.7	20.4	12.3	11.8	14.3	19.5	22.7	<.001*
Anxiety/Depression	14.3	14.8	17.5	14.2	12.6	12.0	14.4	15.5	.002*
EQ-5D VAS	n=3,761	n=540	n=605	n=388	n=485	n=844	n=351	n=548	<.001*
Mean	76.15	78.21	73.29	77.28	79.50	77.36	74.32	72.80	
SD	18.97	17.12	19.93	19.90	17.48	18.55	19.56	19.57	
EQ-5D Index	n=3,690	n=540	n=583	n=383	n=489	n=828	n=344	n=523	<.001*
Mean	.90	.92	.89	.91	.92	.91	.88	.87	
SD	.15	.14	.15	.14	.15	.14	.16	.18	

Notes: Data for EQ-5D-dimensions represent relative percentages of patients, who indicated moderate to severe problems with respect to each dimension. Significant differences were calculated using Kruskal-Wallis-tests for independent samples.

Table 3. Patient characteristics and their correspondence with EQ-5D VAS and index values.

Variables	EQ-5D VAS				EQ-5D Index			
	Mean	SD	β	p	Mean	SD	β	p
Age group			-.32	<.001*			-.22	<.001*
18-34	83.46	14.75			.94	.11		
35-64	73.44	18.99			.89	.15		
65+	62.23	20.83			.82	.21		
Sex			.01	<.001*			.04	.004
Female	76.11	19.07			.90	.15		
Male	76.55	18.85			.91	.14		
Residence			.02	.084			.03	.060
City	76.30	17.49			.90	.15		
Town	77.08	18.26			.90	.15		
Rural	76.01	19.46			.90	.15		
Medication			-.22	<.001*			-.19	<.001*
No	79.16	17.13			.92	.13		
Yes	65.17	20.69			.83	.20		

Notes: Multivariate analysis was performed using OLS-regression models with EQ-5D VAS and Index values as dependent variables.

Table 4. Impact of medical features with respect to EQ-5D-dimensions.

Variable	n	Mobility n=3,070	Self-Care n=3,073	Usual activities n=3,068	Pain/discomfort n=3,051	Anxiety/depression n=3,061
Comorbidities						
Cardiac Comorbidities	1,463	.302* (.25-.36)	.525* (.38-.73)	.348* (.29-.41)	.331* (.28-.39)	.467* (.40-.54)
Non-Cardiac Comorbidities	819	.263* (.22-.32)	.281* (.20-.39)	.222* (.18-.27)	.311* (.26-.37)	.243* (.20-.29)
Cyanosis						
Cyanotic	744	.904 (.49-1.68)	.396 (.12-1.26)	.880 (.50-1.56)	1.088 (.65-1.82)	.850 (.51-1.41)
Acyanotic	2,176	1.452 (.70-3.02)	.774 (.20-3.04)	1.207 (.63-2.30)	1.011 (.58-1.77)	.695 (.40-1.19)
Warnes class						
Simple	1,722	1.396 (.69-2.84)	.707 (.18-2.84)	1.109 (.60-2.06)	.984 (.57-1.69)	.739 (.44-1.24)
Moderate	650	.848 (.50-1.45)	.538 (.17-1.69)	.985 (.60-1.61)	.884 (.57-1.37)	.921 (.60-1.41)
Severe	406	.384* (.19-.76)	.148* (.04-.58)	.710 (.39-1.30)	.620 (.36-1.08)	.742 (.43-1.27)

Notes: Displayed are odds ratios, upper and lower bounds (95% CI) respectively which were obtained from several ordered logistic regressions using EQ-dimensions as dependent variable.

* $p < .05$

1
2
3 **Figures**
4

5 **Figure 1: Distribution of scores for Mobility**
6

7 **Figure 2: Distribution of scores for Self-Care**
8

9 **Figure 3: Distribution of scores for Usual Activities**
10

11 **Figure 4: Distribution of scores for Pain/Discomfort**
12

13 **Figure 5: Distribution of scores for Anxiety/Depression**
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Distribution of scores for Mobility




Figure 2: Distribution of scores for Self-Care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Distribution of scores for Usual Activities




Figure 4: Distribution of scores for Pain/Discomfort

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5: Distribution of scores for Anxiety/Depression

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4/5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	4/5
		(b) Describe any methods used to examine subgroups and interactions	4/5
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5
		(b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	5-6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	n/a

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	5-6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	5-6
Discussion			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The "Well-being paradox" revisited: A cross-sectional study of quality of life in over 4,000 adults with congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049531.R1
Article Type:	Original research
Date Submitted by the Author:	27-Apr-2021
Complete List of Authors:	Andonian, Caroline; German Heart Centre Munich, Freiling, Sebastian; German Heart Centre Munich, Achenbach, Stephan; University of Erlangen, Cardiology Ewert, Peter; German Heart Centre, Paediatric Cardiology Gundlach, Ulrike; University of Erlangen, Cardiology Hoerer, Jürgen; Deutsches Herzzentrum München, Cardiac Surgery Kaemmerer, Harald Pieper, Lars; Technische Universität Dresden, Behavioural Epidemiology Weyand, Michael; University of Erlangen, Department of Cardiothoracic surgery Neidenbach, Rhoia ; Deutsches Herzzentrum Munchen Beckmann, Jürgen; Technische Universität München, Sport- and Health Sciences
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology, Evidence based practice, Patient-centred medicine
Keywords:	Cardiac Epidemiology < CARDIOLOGY, PREVENTIVE MEDICINE, Adult cardiology < CARDIOLOGY, Congenital heart disease < CARDIOLOGY, EPIDEMIOLOGY, MENTAL HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The "Well-being paradox" revisited: A cross-sectional study of quality of life in over 4,000 adults with congenital heart disease

Caroline Andonian^{1,2}, Sebastian Freilinger¹, S. Achenbach³, Peter Ewert¹, U. Gundlach³, Jürgen Hörer⁴, Harald Kaemmerer¹, Lars Pieper⁵, Michael Weyand⁶, Rhoia Clara Neidenbach^{1*}, Jürgen Beckmann^{2,7,8*}

¹ Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Germany

² Department of Sport and Health Sciences, Chair of Sport Psychology, Technical University Munich, Germany

³ Department of Cardiology, University of Erlangen, Erlangen, Germany

⁴ Department for Congenital and Pediatric Heart Surgery, German Heart Center Munich, Technical University Munich, Germany, Division for Congenital and Pediatric Heart Surgery, University Hospital Großhadern, Ludwig-Maximilians University, Munich, Germany

⁵ Department of Behavioral Epidemiology, Technical University of Dresden, Germany

⁶ Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany

⁷ School of Human Movement and Nutrition Sciences, University of Queensland, Australia

⁸ Health Research Institute, University of Limerick, Ireland

* The last two authors contributed as last authors.

Correspondence to: Caroline Andonian, M.Sc., M.Sc., Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Germany, Email: andonian@dhm.mhn.de

Abstract

Objective: The present cross-sectional study investigated quality of life (QOL) in a large cohort of German adults with congenital heart disease (ACHD) in association with patient-related and clinical variables.

Design: Cross-sectional survey.

Participants: Between 2016 and 2019, a representative sample of 4,014 adults with various forms of CHD was retrospectively analyzed. Inclusion criteria were confirmed diagnosis of CHD, participant age 18 years and older, necessary physical, cognitive and language capabilities to complete self-report questionnaires.

Primary and secondary outcome measures: QOL was assessed using the EQ-5D-5L. Sociodemographic and medical information was obtained by a self-devised questionnaire. Associations of QOL with patient-reported clinical and sociodemographic variables were quantified using multiple regression analysis and multiple ordinal logit models.

Results: Overall, ACHD (41.8 ± 17.2 years; 46.5% female) reported a good QOL comparable to German population norms. The most frequently reported complaints occurred in the dimensions pain/discomfort (mean: 16.3, SD: p<0.001) and anxiety/depression (mean: 14.3, p<0.001). QOL differed significantly within ACHD subgroups, with patients affected by pre-tricuspid shunt lesions indicating the most significant impairments (p<0.001). Older age, female sex, medication intake and the presence of comorbidities, were associated with significant reductions in QOL (p<0.001). CHD severity was positively associated with QOL within the dimensions of self-care (odds ratio [OR] 0.148, 95% CI .04-.58) and mobility (odds ratio [OR] 0.384, 95% CI .19-.76).

Conclusion: Current findings temper widely held assumptions among clinicians and confirm that ACHD experience a generally good QOL. However, specific subgroups may require additional support to cope with disease-related challenges. The negative correlation of QOL with age is especially alarming as the population of ACHD is expected to grow older in the future.

Keywords: adults with congenital heart disease; psychological situation; quality of life; prevention; EQ5D

1 **Strengths and Limitations**

- 2 • First study of its kind exploring quality of life (QOL) among 4,014 patients with different
3 medical and patient-related backgrounds.
- 4 • Uniform conceptualization of QOL based on EQ-5D-5L, which is a highly reliable and valid
5 outcome measure within the cardiovascular area.
- 6 • Present findings help clinicians to identify specific subsets of patients who require extra
7 psychological support and therefore constitute a major step in paving the way towards
8 integrative cardiac care.
- 9 • Causal inferences are not possible due to the cross-sectional design of this study.
- 10 • Ambiguous findings open new avenues for future research in understanding the construction of
11 self-rated health despite or as a consequence of CHD.

1 Introduction

2 Congenital heart defects (CHD) are the most common isolated inborn organ malformations and affect
3 1.35–1.5 million children each year. Although 90% of patients with CHD survive into adulthood, many of
4 them are not cured and need to adapt to their chronic medical condition throughout their lives [1].
5 Besides symptoms related to their heart disease, lifelong psychosocial impairments may seriously
6 impact the patients' perceived quality of life (QOL) [2]. While clinical research traditionally focused on
7 objective medical outcomes, the relevance of QOL and various related patient-reported outcomes
8 is increasingly recognized in the evaluation of care for adults with congenital heart disease (ACHD) [3].
9 Research on QOL in ACHD is still relatively scarce and not conclusive. Empirical findings indicate that
10 QOL among ACHD is compromised by sociodemographic factors (unemployment, older age, single
11 status), psychological features (negative illness perceptions, distressed personality) and medical
12 characteristics (e.g. hospitalization, worse functional status). QOL has been found to be positively
13 associated with higher socioeconomic and educational status, stronger social support, better functional
14 class, better knowledge of CHD, stronger sense of coherence as well as the absence of cardiac surgery.
15 Existing findings are inconsistent regarding cardiovascular status, medication, age, and gender, although
16 these variables appeared to be the most frequently investigated determinants [4].
17 These inconsistent results of existing research on QOL in ACHD can be attributed to a lack of a clear
18 conceptual background, inconsistent methods and insufficient sample sizes [4]. Additionally, the high
19 heterogeneity of ACHD constitutes a substantial confounding factor due to their great anatomical and
20 clinical disease complexity. Most studies on QOL in ACHD focused on specific subgroups of patients
21 which limits their informational value. Consequently, clinical parameters were not sufficiently examined
22 to explain potential differences in QOL by the underlying diagnosis or severity of CHD. Although a
23 recent review attests temporal qualitative improvements in QOL studies over the last decades, the
24 current research situation still fails to meet scientific quality criteria [5].
25 The present study aimed to assess QOL within a large sample of ACHD in Germany and examine
26 potential determinants of QOL in terms of patient-related and medical characteristics. Identifying
27 determinants of QOL along with special needs of ACHD could advance the improvement of health care
28 for this growing patient population.

29 Methods

30 Design

31 The present study represents a sub-analysis of the nationwide VEMAH initiative (“Versorgungssituation
32 von Erwachsenen mit angeborenen Herzfehlern”, engl. “Medical Care Situation of ACHD”). Detailed
33 information on the rationale, design, and methods is documented in a former published paper

1 [6]. VEMAH is a multicenter, cross-sectional study to assess the health care situation of ACHD in
2 Germany. Coordination of VEMAH was initiated and carried out by the German Heart Center Munich.

3 Population

4 A questionnaire package was consecutively addressed to ACHD presenting at the Department of
5 Congenital Heart Disease and Pediatric Cardiology of the German Heart Center Munich and the
6 Department of Cardiology of the University of Erlangen. Additionally, the health insurance provider
7 “AOK Bayern” distributed questionnaires to their policyholders with CHD in Bavaria, and the “National
8 Register for Congenital Heart Defects” in Berlin, Germany, invited its members to participate in the
9 study online. Guidelines on good clinical practice and data protection guidelines were followed.
10 Inclusion criteria were: (1) confirmed diagnosis of CHD according to the definition of Thiene &
11 Frescura, [7] (2) participant age 18 years and older, (3) necessary physical, cognitive and language
12 capabilities to complete self-report questionnaires.

13 Measures

14 Patients completed a questionnaire either in person, online or by mail. Data collection took place
15 between 2016 and 2019. QOL was measured using the generic questionnaire EQ-5D-5L[8].

16 I. *Demographic and clinical information*

17 Sociodemographic and medical information was obtained by a self-devised questionnaire. Medical
18 variables included leading CHD, medication, presence of cyanosis, (non-) cardiac comorbidities and
19 hereditary diseases. Following the recommendations of the American College of Cardiology, patients
20 were divided into three severity groups based on their CHD diagnosis (ACC) [9].

21 II. *Quality of Life (EQ-5D-5L)*

22 QOL was measured using the updated five-level version of the EQ-5D [8] which provides a simple,
23 generic measure of a patient’s perceived health status. The EQ-5D-5L consists of a descriptive system
24 questionnaire and a visual analogue scale (VAS). The descriptive system comprises five dimensions:
25 mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each patient was asked to
26 indicate his perceived impairments on a 5-point Likert scale ranging from “no problems” to “extreme
27 problems/unable”. Responses were converted into a single weighted index score (EQ-5D index) which
28 indicates how good or poor the respondent’s health status is based on existing population norms. A value
29 set for the EQ-5D-5L, based on a representative sample of the German population, has recently been
30 developed [10]. The VAS indicates a patient’s overall health state on the day of the questionnaire
31 completion. It is a scale which ranges from 0 (“The worst health you can imagine”) to 100 (“The best
32 health you can imagine”) and provides a quantitative measure of a patient’s perceived health. The EQ-

1 5D-5L proved to be a reliable and valid method for measuring QOL in cardiovascular populations
2 (Cronbach's alpha = 0.856) [11].

3 Statistical analysis

4 Statistical analysis was performed using IBM SPSS Statistics 24.0 (IBM, Armond, New York, United
5 States). Descriptive measures were calculated for sample characteristics, including patient reported
6 sociodemographic and medical variables (absolute and relative frequencies, mean and standard
7 deviations). The relationships between CHD diagnosis groups and EQ-5D-index values, including the
8 underlying dimensions mobility, self-care, usual activities, pain/discomfort and anxiety/depression were
9 analysed. The comparison of ordinaly scaled values was based on cumulative frequencies representing
10 the relative proportion of patients with moderate to severe symptoms on the specific dimensions.
11 Kruskal-Wallis-tests were applied to reveal significant differences between EQ-5D-dimensions and
12 metric index values. Furthermore, the relationship between both EQ-5D VAS scores and dedicated index
13 values was analysed with respect to various patient characteristics. Multiple regression models using
14 Ordinary least squares (OLS)-estimates were calculated, while bivariate Pearson-coefficients were used
15 to analyse the correlation between VAS and index scores. Finally, multiple ordinal logit models were
16 applied to identify significant predictors of the respective QOL dimensions. For all tests, the statistical
17 significance level was set at $p < 0.05$.

18 Patient and Public Involvement

19 Neither patients nor the public were involved in the design and conduct of this research. The
20 methodology of this research was adapted in multidisciplinary collaboration.

21 Results

22 Sample characteristics

23 A total of 4,014 patients was analysed (46.5% female) (**Table 1**). The mean age of ACHD was $41.8 \pm$
24 17.2 [18-97] years. Patients were subclassified according to the underlying CHD into six main groups,
25 consisting of complex CHD (n=581); pre-tricuspid shunts (n=621); post-tricuspid shunts (n=406); right
26 heart or pulmonary artery anomalies (n=526); left heart or aortic anomalies (n=898); and miscellaneous
27 CHD (n=602). 15.4 % of patients (n=602) presented with cyanosis. The severity of CHD was determined
28 according to the Warnes classification system as simple (n=1,722, 62.0%), intermediate (n=650, 23.4%)
29 or severe (n=406, 14.6%) [12].

1 QOL and ACHD

2 EQ-5D dimensions were found to be differently associated with CHD subgroups. Significant differences
3 between the underlying diagnosis were found on all dimensions ($p<.001$). Compared to all other
4 subgroups, pre-tricuspid shunts were particularly impaired in mobility, daily activities, pain/discomfort
5 and anxiety/depression (**Table 2**). In contrast, complex CHD showed the least problems on the respective
6 descriptive dimensions (**Figure 1-5**).

7 Similar results were reflected by EQ-5D VAS and index values ($p<.001$) with EQ-5D VAS values being
8 highest in patients with right heart/pulmonary artery anomalies and complex CHD and lowest in patients
9 with pre-tricuspid shunts. Observed differences were less extreme between descriptive EQ-5D index
10 values. Both EQ-5D values were positively correlated ($r=.623$, $p<.001$), with coefficients being the
11 lowest for patients with complex CHD ($r=.579$, $p<.001$) and highest for patients with left heart/aortic
12 anomalies ($r=.653$, $p<.001$). Variations in QOL were observed depending on the type of measurement
13 which was applied. Accordingly, the mean VAS score displayed a significantly lower QOL than the
14 descriptive EQ-5D index value.

15 Patient-related Determinants of QOL

16 OLS-Regression models were applied to analyse relationships of sociodemographic variables with EQ-
17 5D VAS and index values (**Table 3**). At the 5% level of significance, age had the highest negative impact
18 on VAS values ($\beta=-.32$) and Index values ($\beta=-.22$). Thus, QOL decreased with advancing age. Patients
19 aged 65+ years indicated the lowest values on both scales. Means for both EQ-values were slightly
20 higher in male than in female patients. Medication intake had significant negative effects on QOL in
21 both measures. Model fit was slightly higher for the dependent variable in VAS values ($R^2=.190$) than
22 EQ-5D index values ($R^2=.112$).

23 CHD-related Determinants of QOL

24 EQ-5D-dimensions were analysed more specifically in regard to different medical features such as
25 connective tissue disease diseases with cardiovascular involvement, cyanotic status and severity codes
26 of CHD. Several ordered logistic regression models were applied using each of the five dimensions as
27 dependent variables (**Table 4**). Generally, patients with comorbidities had significantly increased odds
28 of reporting problems on all dimensions than patients without comorbidities ($p<.05$). Non-cardiac
29 comorbidities accounted for significantly higher odds of having problems than cardiac comorbidities.
30 No significant effects could be observed for cyanotic status. Furthermore, regression models showed no
31 effects for patients with simple or moderate disease severity classes. Apparently, severely classified
32 patients indicated decreased odds of suffering from issues related to mobility or self-care than patients
33 in lower Warnes' classes.

1 Discussion

2 QOL is one of the most important measures used to assess the psychosocial impact of chronic disease
3 on a patient's life. This is the first study to investigate patient reported QOL within a cohort of 4,014
4 patients encompassing a broad spectrum of CHD. QOL in ACHD was assessed by utilizing the EQ-5D-
5 5L, a highly reliable and valid outcome measure within the cardiovascular area [13]. It comprises
6 two types of measurement and therefore provides a global view on QOL in terms of general life
7 satisfaction. This allowed to reveal genuine differences in QOL among patients with different medical
8 and sociodemographic backgrounds, regardless of methodological considerations. Within the context of
9 this study, QOL quantifies the influence of CHD on a patient's ability to function and derive personal
10 satisfaction from life.

11 QOL in ACHD

12 In line with previous findings [14], ACHD in general reported a good level of wellbeing which is
13 comparable to German population norms [15]. The two-fold measure of QOL revealed that the type of
14 measurement affects QOL scores differently. Apparently, the overall VAS score indicated a significantly
15 lower QOL than the descriptive EQ-5D index value. One explanation for this discrepancy are differences
16 in the QOL coverage of both measures. It can be assumed that the descriptive system encourages a
17 patient to examine QOL from various angles as the system breaks down QOL into various components.
18 Thus, QOL is regarded as a subjective concept being influenced by multiple causal factors [16]. In
19 contrast, VAS picks up a one-dimensional view of perceived health where patients may indicate a higher
20 occurrence of problems by focusing on somatic health restrictions imposed by their CHD. When
21 comparing the quantitative association of CHD with QOL to other chronic disorders, the average
22 reduction in VAS values in the current sample roughly resembles observations of various other heart
23 diseases [15]. In line with previous research, patients most frequently reported problems in the areas of
24 pain/discomfort (16.3%) and anxiety/depression (14.3%) [17]. These rates lie considerably above
25 German population standards, which document symptoms of anxiety/depression in 4.7% of the general
26 public. This result further supports previous research showing that ACHD are specifically prone to
27 increased psychological distress and therefore require additional psychosocial support [18].

28 A closer look at different diagnosis groups reveals, that patients with pre-tricuspid shunts were
29 particularly impaired in QOL. Comparable data have previously documented that QOL is not necessarily
30 congruent with the complexity or severity of a heart disease. Even mild primary pre-tricuspid shunts can
31 have a considerable negative impact on QOL [19]. Clinical reality shows that pre-tricuspid shunts are
32 often detected incidentally and later in life creating a different psychological situation than diagnosis of
33 CHD early in life. Children, who grew up with the awareness of their CHD, may acquire a greater sense
34 of appreciation for life and expectations consistent with their capabilities and limitations [20].
35 Qualitative research on ACHD indicates that patients perceive the awareness of their childhood
36 condition as a resource to re-evaluate life priorities and develop a new life perspective [21]. A recent

1 study has further established, that sense of coherence is a highly significant predictor of QOL in ACHD
2 [22]. Based on theoretical considerations, SOC develops during childhood and is thought to be fully
3 developed by the age of 30 years [23]. Patients who may be diagnosed later in life may have missed the
4 chance to develop and refine coping mechanisms and may therefore experience the effects of their CHD
5 more negatively leading to higher emotional distress. Life-stage variables, such as age at diagnosis or
6 years of survival, need to be further investigated as possible determinants of QOL.

7 Socioeconomic determinants of QOL

8 Despite good overall QOL, EQ-5D index and VAS values deteriorated with increasing age. This might
9 be explained by the uncertainty in disease prognosis manifesting itself in an increased sense of
10 vulnerability in this patient group [24]. Most patients with CHD are known to do well in the first decades
11 of life until they eventually develop unexpected age and disease-related comorbidities. This
12 development deserves special attention as the group of ACHD is expected to grow steadily in the future
13 [1].

14 In contrast to previous findings [14], the present study revealed modest gender-related differences in
15 QOL. Females were more likely to report poor QOL than males. These findings may be attributed to
16 psychosocial factors rather than gender per se [25]. In general, gender is found to influence health
17 expectations, health behaviours and perceived health outcomes [26]. Females may face a triple burden
18 shouldering family responsibility, professional ambition and demands of their chronic disease. Research
19 has demonstrated that females were less likely to return to work, more likely to decline psychological
20 counselling and more socially isolated than males [27]. It has also been argued that females were more
21 willing to disclose problems than males concerning their QOL, which may partly explain the difference
22 in their QOL [26]. Engelfriet et al. (2005) also showed that females with CHD were more often
23 symptomatic and presented functional impairments, despite a higher overall mortality in males over a
24 5-year period [28]. Gender disparities in patient-provider communication and dissatisfaction with health
25 care might be another reason for decreased QOL in females. They might have higher expectations and
26 a stronger demand for more participatory encounters with their healthcare providers [25]. Improved
27 recognition and understanding of these gender-specific differences and challenges among ACHD is vital
28 to improve their cardiovascular health over the long-term.

29 Reported medication intake was inversely associated with QOL in the present study This appears
30 plausible because extensive or inappropriate medication can lead to severe side effects and even higher
31 morbidity which may considerably impair QOL [29]. Aside from incorrect pharmaceutical treatment,
32 the daily intake of medication is a constant reminder of illness and may have a negative impact on life
33 satisfaction. Consequently, medication may either be a facilitator by providing new opportunities or an
34 intensifier of problems by adverse psychological and somatic side effects.

1 **Clinical determinants of QOL**

2 Despite all advances in cardiac care, many CHD patients are left with significant residual, sequelae or
3 complications from the underlying anomaly [9, 30]. The impact of comorbidities in ACHD is largely
4 underestimated [31]. The current study indicates that the presence of comorbidities increases the risk of
5 problems on all dimensions of the EQ-5D. It is conceivable that affected patients report a lower health
6 status since they may experience serious restrictions in various life domains. As comorbidities become
7 increasingly dominant with advancing age, they may also explain the recorded deterioration of QOL
8 with age in the present sample.

9 It is remarkable that patients with a more complex CHD scored significantly better in QOL domains.
10 Until now, research has failed to demonstrate a clear-cut correlation between disease complexity and
11 QOL [4]. Although the present finding may seem counterintuitive at first, there are various possible
12 explanations for a better QOL in the light of a chronic condition. Keyes' two continua model of mental
13 health [32] provides an important framework for explaining why patients might experience a good QOL
14 despite their CHD. Accordingly, mental health is a complex state resulting from an interplay of
15 environmental and psychological factors that have a profound influence on one's subjective wellbeing.
16 Keyes' model holds that mental health (sometimes referred to as mental wellbeing) and mental illness
17 are orthogonally related phenomena and not two endpoints of one single continuum. Although the
18 current state of research confirms elevated levels of mental illness among ACHD [18], this does not
19 necessarily imply impaired mental wellbeing or decreased QOL among these patients. Furthermore, the
20 disability paradox explains why individuals may perceive a high QOL despite serious limitations.
21 Accordingly, QOL depends upon finding a balance in life and maintaining harmonious social
22 relationships [33]. The characteristics associated with a severe CHD may potentially include favourable
23 and compromising factors and thus explain both extremes of QOL in ACHD. Lastly, growing up with a
24 CHD can lead to a so-called "response shift" in terms of redefining priorities in one's life [34]. It is
25 perceivable that patients develop different values from those of healthy persons in the face of a life-
26 threatening, chronic illness. In this context, Sprangers et. al (1999) proposed a theoretical model to
27 clarify and predict changes in QOL as a result of various dispositional characteristics, a patient's health
28 status and mechanisms to accommodate to these changes [35].

29 Despite the extensive power of the present study, current results should be interpreted with caution due
30 to certain limitations. The study was retrospective and cross-sectional in nature and does not allow to
31 disentangle any conclusions about the directionality of effects or the development of QOL over time.
32 Since all information was based on patient-reported outcomes, medical data may have been classified
33 incorrectly due to a patient's limited knowledge of his or her condition. Consequently, surgical status of
34 patients could not be identified. Subsequently, it would be advisable to synchronize these data with
35 medical records in order to disentangle the effects of empirical-medical observations on QOL. As the
36 enrolment was voluntary, selection bias could not be excluded and may hamper representativeness.
37 Further, this study was performed at a tertiary care center for ACHD which does not reflect the typical

1 population of CHD. Further doubts must be raised about whether the applied EQ-5D-5L provides an
2 accurate tool to evaluate QOL among AHCD. Although the updated 5L version demonstrates superior
3 performance compared to its predecessor, psychometric properties in terms of high ceiling effects and
4 weak discriminatory power have previously been questioned [36]. It has further been shown that the
5 choice of value set has an impact on EQ-5D scores [37]. Since the present study used a population-based
6 value set to construct QOL estimates, we strongly encourage to re-evaluate current findings on the basis
7 of experience-based value sets. Further, the inventory was administered in three different ways.
8 However, measurement invariance across the survey methods was not tested and the equivalence across
9 the survey methods remains questionable. Since the primary aim of this study was to assess clinical
10 determinants of QOL, sociodemographic variables were not explicitly reviewed within the present
11 analysis. Based on the German healthcare system, the depicted sociodemographic variables are crucial
12 indicators of access to medical supply and were therefore separately analyzed. Given previously
13 documented associations between sociodemographic factors and QOL, generalization of the conclusions
14 and transmission to patients from differing socioeconomic conditions is debatable. The present survey
15 assessed biological sex with a binary value. Given the increasing incidence of transgender and gender
16 non-binary individuals and that large health disparities exist for this population [38], future research
17 should increasingly expand measures of sex/gender to be trans inclusive. Finally, no control group was
18 involved, and data could only be compared to published national EQ-5D studies.

19 **Conclusion**

20 The present study shows that ACHD experience – on aggregate – a good QOL which is indistinguishable
21 from healthy individuals. Against expectation, patients with complex CHD scored higher on QOL.
22 However, specific subgroups of patients indicate significant reductions in QOL and may require extra
23 support in their care to cope with challenges associated with their underlying CHD. The negative
24 correlation with age deserves particular attention as it could lead to a decrease in QOL with the growing
25 median age of this patient population.

26 QOL is regarded as a central target in the treatment of chronically ill patients. This study supports the
27 need to further assess and promote mental wellbeing in ACHD to safeguard surgical successes of the
28 past decades which have ensured the survival of CHD patients into adulthood. Successful treatment
29 implies not only an increased length of survival but also enhanced subjective wellbeing and QOL.

30 **Declarations**

31 **Funding:** This work was supported by the German Heart Foundation (“Deutsche Herzstiftung e.V.”)
32 (grant number F-30-15), the patient organization “Herzkind e. V.”, Actelion Pharmaceuticals Germany
33 GmbH (grant number MED-2015-495) and the German health care insurance AOK-Bayern

1 **Competing Interest:** The authors have no conflicts of interest to declare.

2 **Ethics Approval:** The study was part of the nationwide VEMAH project which was approved on
3 04/05/2016 by the ethical committee of the Technical University of Munich (157/16S).

4 **Consent to participate:** Informed consent was obtained from all individual participants included in the
5 study.

6 **Consent for publication:** All authors consent to the publication of the manuscript in the Journal
7 “Clinical Research in Cardiology”.

8 **Availability of data and material:** The datasets generated during and/or analysed during the current
9 study are available from the corresponding author on reasonable request.

10 **Author Contributions:**

11 (1) *Conception and design:* CA, HK, JB

12 (2) *Administrative support:* CA, SF, SA, PE, UG, JH, HK, LP, MW, RN, JB

13 (3) *Collection and assembly of data:* CA, SF, SA, UG, MW

14 (4) *Data analysis and interpretation:* CA; SF

15 (5) *Manuscript writing:* CA, JB

16 (6) *Final approval of manuscript:* CA, SF, SA, PE, UG, JH, HK, LP, MW, RN, JB

17 .

1 References

1. Zimmerman MS, Smith AGC, Sable CA, Echko MM, Wilner LB, Olsen HE, et al. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Child Adolescent Health*. 2020;4(3):185-200.
2. Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. *J American heart journal*. 2005;150(2):193-201.
3. Hunter AL, Swan L. Quality of life in adults living with congenital heart disease: beyond morbidity and mortality. *Journal of thoracic disease*. 2016;8(12):E1632.
4. Moons P, Luyckx K. Quality-of-life research in adult patients with congenital heart disease: current status and the way forward. *J Acta Paediatrica*. 2019;108(10):1765-72.
5. Bratt E-L, Moons P. Forty years of quality-of-life research in congenital heart disease: Temporal trends in conceptual and methodological rigor. *International journal of cardiology*. 2015;195:1-6.
6. Neidenbach R, Achenbach S, Andonian C, Bauer UM, Ewert P, Freilinger S, et al. Systematic assessment of health care perception in adults with congenital heart disease in Germany. *Cardiovascular Diagnosis Therapy*. 2021.
7. Thiene G, Frescura C. Anatomical and pathophysiological classification of congenital heart disease. *Cardiovascular Pathology*. 2010;19(5):259-74.
8. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *J Quality of life research*. 2011;20(10):1727-36.
9. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2018:CIR. 0000000000000603.
10. Grochtdreis T, Dams J, König H-H, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. *J The European Journal of Health Economics*. 2019;20(6):933-44.
11. Boczor S, Daubmann A, Eisele M, Blozik E, Scherer M. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L™. *J BMC public health*. 2019;19(1):1464.
12. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI, et al. Task force 1: the changing profile of congenital heart disease in adult life. *Journal of the American College of Cardiology*. 2001;37(5):1170-5.
13. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. *Health quality of life outcomes*. 2010;8(1):13.
14. Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, et al. Quality of life of adults with congenital heart disease in 15 countries: evaluating country-specific characteristics. *Journal of the American College of Cardiology*. 2016;67(19):2237-45.
15. Huber MB, Reitmeir P, Vogelmann M, Leidl R. EQ-5D-5L in the general German population: comparison and evaluation of three yearly cross-section surveys. *International journal of environmental research public health*. 2016;13(3):343.
16. Moons P, Deyk KV, Bleser LD, Marquet K, Raes E, Geest SD, et al. Quality of life and health status in adults with congenital heart disease: a direct comparison with healthy counterparts. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2006;13(3):407-13.

17. Berghammer M, Karlsson J, Ekman I, Eriksson P, Dellborg M. Self-reported health status (EQ-5D) in adults with congenital heart disease. *J International journal of cardiology*. 2013;165(3):537-43.
18. Andonian C, Beckmann J, Biber S, Ewert P, Freilinger S, Kaemmerer H, et al. Current research status on the psychological situation of adults with congenital heart disease. *2018;8(6):799*.
19. Vigl M, Niggemeyer E, Hager A, Schwedler G, Kropf S, Bauer U. The importance of socio-demographic factors for the quality of life of adults with congenital heart disease. *Quality of Life Research*. 2011;20(2):169-77.
20. Moons P, Norekvål TM. Is sense of coherence a pathway for improving the quality of life of patients who grow up with chronic diseases? A hypothesis. *J European Journal of Cardiovascular Nursing*. 2006;5(1):16-20.
21. Moreland P, Santacroce SJ. Illness uncertainty and posttraumatic stress in young adults with congenital heart disease. *The Journal of cardiovascular nursing*. 2018;33(4):356.
22. Moons P, Apers S, Kovacs AH, Thomet C, Budts W, Enomoto J, et al. Sense of coherence in adults with congenital heart disease in 15 countries: Patient characteristics, cultural dimensions and quality of life. *European Journal of Cardiovascular Nursing*. 2021;20(1):48-55.
23. Antonovsky A. *Unraveling the mystery of health: How people manage stress and stay well*: Jossey-bass; 1987.
24. Saliba Z, Butera G, Bonnet D, Bonhoeffer P, Villain E, Kachaner J, et al. Quality of life and perceived health status in surviving adults with univentricular heart. *%J Heart*. 2001;86(1):69-73.
25. Chen C-A, Liao S-C, Wang J-K, Chang C-I, Chiu S, Chen Y-S, et al. Quality of life in adults with congenital heart disease: biopsychosocial determinants and sex-related differences. *Heart*. 2011;97(1):38-43.
26. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. *Journal of general internal medicine*. 2001;16(4):266-75.
27. Ford ES, Mokdad AH, Li C, McGuire LC, Strine TW, Okoro CA, et al. Gender differences in coronary heart disease and health-related quality of life: findings from 10 states from the 2004 behavioral risk factor surveillance system. *J Journal of Women's Health*. 2008;17(5):757-68.
28. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilén U, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period: the Euro Heart Survey on adult congenital heart disease. *J European heart journal*. 2005;26(21):2325-33.
29. Olsson IN, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. *J Health quality of life outcomes*. 2011;9(1):95.
30. Perloff JK, Warnes CA. Challenges posed by adults with repaired congenital heart disease. *Circulation*. 2001;103(21):2637-43.
31. Neidenbach RC, Lummert E, Vigl M, Zchoval R, Fischereder M, Engelhardt A, et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovascular Diagnosis and Therapy*. 2018.
32. Keyes CL. The mental health continuum: From languishing to flourishing in life. *J Journal of health social behavior*. 2002:207-22.
33. Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. *Social science & medicine*. 1999;48(8):977-88.
34. Rapkin BD, Schwartz CE. Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift. *Health and quality of life outcomes*. 2004;2(1):14.

- 1
2
3
4 1 35. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of
5 2 life research: a theoretical model. *J Social science medicine*. 1999;48(11):1507-15.
6 3 36. Feng Y, Parkin D, Devlin NJ. Assessing the performance of the EQ-VAS in the NHS
7 4 PROMs programme. *Quality of Life Research*. 2014;23(3):977-89.
8 5 37. Leidl R, Reitmeir P. An experience-based value set for the EQ-5D-5L in Germany.
9 6 *Value in Health*. 2017;20(8):1150-6.
10 7 38. Bauer GR, Braimoh J, Scheim AI, Dharma C. Transgender-inclusive measures of
11 8 sex/gender for population surveys: Mixed-methods evaluation and recommendations. *PloS*
12 9 *one*. 2017;12(5):e0178043.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Characteristics of the underlying study population.

Variables	n (%)
Age group (n=3,903)	
18-34	1,663 (42.6)
35-64	1,733 (44.4)
65+	507 (13.0)
Gender (n=3,898)	
male	2,087 (53.5)
female	1,811 (46.5)
Residence (n=3,855)	
City	775 (20.1)
Town	590 (15.3)
Rural	2,490 (64.6)
Insurance (n=3,905)	
Public	3,679 (94.2)
Private	219 (5.6)
No Insurance	7 (.2)
Type of CHD (n=4,014)	
Complex Congenital Heart Defects	581 (14.5)
Primary Pre-Tricuspid Shunts	621 (15.5)
Primary post-Tricuspid Shunts	406 (10.1)
Right Heart / Pulmonary artery anomalies	526 (13.1)
Left Heart / Aortic anomalies	898 (22.4)
Miscellaneous CHD	602 (15.0)
Unclassifiable	380 (9.5)
Warnes Class (n=2,778)	
Simple	1,722 (62.0)
Moderate	650 (23.4)
Severe	406 (14.6)

Table 2. Leading diagnosis of CHD and EQ-5D-results.

EQ-5D	Total	Complex Congenital Heart Defects	Primary pre- tricuspid shunts	Primary post- tricuspid shunts	Right Heart / pulmonary artery anomalies	Left Heart / aortic anomalies	Unclassifiable	Miscellaneous	p-Value
Dimension	n=4,014	n=581	n=621	n=406	n=526	n=898	n=380	n=602	
Mobility	12.2	8.6	13.6	10.4	9.6	10.5	15.0	16.6	<.001*
Self-Care	3.5	2.0	3.0	2.3	3.2	3.5	4.4	5.4	.017*
Usual activities	13.2	13.7	13.5	11.2	12.6	11.1	14.1	16.8	<.001*
Pain/Discomfort	16.3	13.7	20.4	12.3	11.8	14.3	19.5	22.7	<.001*
Anxiety/Depression	14.3	14.8	17.5	14.2	12.6	12.0	14.4	15.5	.002*
EQ-5D VAS	n=3,761	n=540	n=605	n=388	n=485	n=844	n=351	n=548	<.001*
Mean	76.15	78.21	73.29	77.28	79.50	77.36	74.32	72.80	
SD	18.97	17.12	19.93	19.90	17.48	18.55	19.56	19.57	
EQ-5D Index	n=3,690	n=540	n=583	n=383	n=489	n=828	n=344	n=523	<.001*
Mean	.90	.92	.89	.91	.92	.91	.88	.87	
SD	.15	.14	.15	.14	.15	.14	.16	.18	

Notes: Data for EQ-5D-dimensions represent relative percentages of patients, who indicated moderate to severe problems with respect to each dimension. Significant differences were calculated using Kruskal-Wallis-tests for independent samples.

Table 3. Patient characteristics and their correspondence with EQ-5D VAS and index values.

Variables	EQ-5D VAS				EQ-5D Index			
	Mean	SD	β	p	Mean	SD	β	p
Age group			-.32	<.001*			-.22	<.001*
18-34	83.46	14.75			.94	.11		
35-64	73.44	18.99			.89	.15		
65+	62.23	20.83			.82	.21		
Sex			.01	<.001*			.04	.004
Female	76.11	19.07			.90	.15		
Male	76.55	18.85			.91	.14		
Residence			.02	.084			.03	.060
City	76.30	17.49			.90	.15		
Town	77.08	18.26			.90	.15		
Rural	76.01	19.46			.90	.15		
Medication			-.22	<.001*			-.19	<.001*
No	79.16	17.13			.92	.13		
Yes	65.17	20.69			.83	.20		

Notes: Multivariate analysis was performed using OLS-regression models with EQ-5D VAS and Index values as dependent variables.

Table 4. Impact of medical features with respect to EQ-5D-dimensions.

Variable	n	Mobility n=3,070	Self- Care n=3,073	Usual activities n=3,068	Pain/discomfort n=3,051	Anxiety/depression n=3,061
Comorbidities						
Cardiac Comorbidities	1,463	.302* (.25-.36)	.525* (.38-.73)	.348* (.29-.41)	.331* (.28-.39)	.467* (.40-.54)
Non-Cardiac Comorbidities	819	.263* (.22-.32)	.281* (.20-.39)	.222* (.18-.27)	.311* (.26-.37)	.243* (.20-.29)
Cyanosis						
Cyanotic	744	.904 (.49-1.68)	.396 (.12-1.26)	.880 (.50-1.56)	1.088 (.65-1.82)	.850 (.51-1.41)
Acyanotic	2,176	1.452 (.70-3.02)	.774 (.20-3.04)	1.207 (.63-2.30)	1.011 (.58-1.77)	.695 (.40-1.19)
Warnes class						
Simple	1,722	1.396 (.69-2.84)	.707 (.18-2.84)	1.109 (.60-2.06)	.984 (.57-1.69)	.739 (.44-1.24)
Moderate	650	.848 (.50-1.45)	.538 (.17-1.69)	.985 (.60-1.61)	.884 (.57-1.37)	.921 (.60-1.41)
Severe	406	.384* (.19-.76)	.148* (.04-.58)	.710 (.39-1.30)	.620 (.36-1.08)	.742 (.43-1.27)

Notes: Displayed are odds ratios, upper and lower bounds (95% CI) respectively which were obtained from several ordered logistic regressions using EQ-dimensions as dependent variable.

* $p < .05$

1
2
3 **Figures**
4

5 **Figure 1: Distribution of scores for Mobility**
6

7 **Figure 2: Distribution of scores for Self-Care**
8

9 **Figure 3: Distribution of scores for Usual Activities**
10

11 **Figure 4: Distribution of scores for Pain/Discomfort**
12

13 **Figure 5: Distribution of scores for Anxiety/Depression**
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1: Distribution of scores for Mobility




Figure 2: Distribution of scores for Self-Care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Distribution of scores for Usual Activities




Figure 4: Distribution of scores for Pain/Discomfort

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5: Distribution of scores for Anxiety/Depression

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4/5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	4/5
		(b) Describe any methods used to examine subgroups and interactions	4/5
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5
		(b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	5-6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	n/a

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	5-6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	5-6
Discussion			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The "Well-being paradox" revisited: A cross-sectional study of quality of life in over 4,000 adults with congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049531.R2
Article Type:	Original research
Date Submitted by the Author:	12-May-2021
Complete List of Authors:	Andonian, Caroline; German Heart Centre Munich, Freiling, Sebastian; German Heart Centre Munich, Achenbach, Stephan; University of Erlangen, Cardiology Ewert, Peter; German Heart Centre, Paediatric Cardiology Gundlach, Ulrike; University of Erlangen, Cardiology Hoerer, Jürgen; Deutsches Herzzentrum München, Cardiac Surgery Kaemmerer, Harald Pieper, Lars; Technische Universität Dresden, Behavioural Epidemiology Weyand, Michael; University of Erlangen, Department of Cardiothoracic surgery Neidenbach, Rhoia ; Deutsches Herzzentrum Munchen Beckmann, Jürgen; Technische Universität München, Sport- and Health Sciences
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology, Evidence based practice, Patient-centred medicine
Keywords:	Cardiac Epidemiology < CARDIOLOGY, PREVENTIVE MEDICINE, Adult cardiology < CARDIOLOGY, Congenital heart disease < CARDIOLOGY, EPIDEMIOLOGY, MENTAL HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The "Well-being paradox" revisited: A cross-sectional study of quality of life in over 4,000 adults with congenital heart disease

Caroline Andonian^{1,2}, Sebastian Freilinger¹, S. Achenbach³, Peter Ewert¹, U. Gundlach³, Jürgen Hoerer⁴, Harald Kaemmerer¹, Lars Pieper⁵, Michael Weyand⁶, Rhoia Clara Neidenbach^{1*}, Jürgen Beckmann^{2,7,8*}

¹ Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Germany

² Department of Sport and Health Sciences, Chair of Sport Psychology, Technical University Munich, Germany

³ Department of Cardiology, University of Erlangen, Erlangen, Germany

⁴ Department for Congenital and Pediatric Heart Surgery, German Heart Center Munich, Technical University Munich, Germany, Division for Congenital and Pediatric Heart Surgery, University Hospital Großhadern, Ludwig-Maximilians University, Munich, Germany

⁵ Department of Behavioral Epidemiology, Technical University of Dresden, Germany

⁶ Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany

⁷ School of Human Movement and Nutrition Sciences, University of Queensland, Australia

⁸ Health Research Institute, University of Limerick, Ireland

* The last two authors contributed as last authors.

Correspondence to: Caroline Andonian, M.Sc., M.Sc., Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Germany, Email: andonian@dhm.mhn.de

Abstract

Objective: The present cross-sectional study investigated quality of life (QOL) in a large cohort of German adults with congenital heart disease (ACHD) in association with patient-related and clinical variables.

Design: Cross-sectional survey.

Participants: Between 2016 and 2019, a representative sample of 4,014 adults with various forms of CHD was retrospectively analyzed. Inclusion criteria were confirmed diagnosis of CHD, participant age 18 years and older, necessary physical, cognitive and language capabilities to complete self-report questionnaires.

Primary and secondary outcome measures: QOL was assessed using the EQ-5D-5L. Sociodemographic and medical information was obtained by a self-devised questionnaire. Associations of QOL with patient-reported clinical and sociodemographic variables were quantified using multiple regression analysis and multiple ordinal logit models.

Results: Overall, ACHD (41.8 ± 17.2 years; 46.5% female) reported a good QOL comparable to German population norms. The most frequently reported complaints occurred in the dimensions pain/discomfort (mean: 16.3, SD: p<0.001) and anxiety/depression (mean: 14.3, p<0.001). QOL differed significantly within ACHD subgroups, with patients affected by pre-tricuspid shunt lesions indicating the most significant impairments (p<0.001). Older age, female sex, medication intake and the presence of comorbidities, were associated with significant reductions in QOL (p<0.001). CHD severity was positively associated with QOL within the dimensions of self-care (odds ratio [OR] 0.148, 95% CI .04-.58) and mobility (odds ratio [OR] 0.384, 95% CI .19-.76).

Conclusion: Current findings temper widely held assumptions among clinicians and confirm that ACHD experience a generally good QOL. However, specific subgroups may require additional support to cope with disease-related challenges. The negative correlation of QOL with age is especially alarming as the population of ACHD is expected to grow older in the future.

Keywords: adults with congenital heart disease; psychological situation; quality of life; prevention; EQ5D

1 **Strengths and Limitations**

- 2 • First study of its kind exploring quality of life (QOL) among 4,014 patients with different
3 medical and patient-related backgrounds.
- 4 • Uniform conceptualization of QOL based on EQ-5D-5L, which is a highly reliable and valid
5 outcome measure within the cardiovascular area.
- 6 • Present findings help clinicians to identify specific subsets of patients who require extra
7 psychological support and therefore constitute a major step in paving the way towards
8 integrative cardiac care.
- 9 • Causal inferences are not possible due to the cross-sectional design of this study.
- 10 • Ambiguous findings open new avenues for future research in understanding the construction of
11 self-rated health despite or as a consequence of CHD.

1 Introduction

2 Congenital heart defects (CHD) are the most common isolated inborn organ malformations and affect
3 1.35–1.5 million children each year. Although 90% of patients with CHD survive into adulthood, many of
4 them are not cured and need to adapt to their chronic medical condition throughout their lives [1].
5 Besides symptoms related to their heart disease, lifelong psychosocial impairments may seriously
6 impact the patients' perceived quality of life (QOL) [2]. While clinical research traditionally focused on
7 objective medical outcomes, the relevance of QOL and various related patient-
8 reported outcomes is increasingly recognized in the evaluation of care for adults with congenital
9 heart disease (ACHD) [3].

10 Research on QOL in ACHD is still relatively scarce and not conclusive. Empirical findings indicate that
11 QOL among ACHD is compromised by sociodemographic factors (unemployment, older age, single
12 status), psychological features (negative illness perceptions, distressed personality) and medical
13 characteristics (e.g. hospitalization, worse functional status). QOL has been found to be positively
14 associated with higher socioeconomic and educational status, stronger social support, better functional
15 class, better knowledge of CHD, stronger sense of coherence as well as the absence of cardiac surgery.
16 Existing findings are inconsistent regarding cardiovascular status, medication, age, and gender, although
17 these variables appeared to be the most frequently investigated determinants [4].

18 These inconsistent results of existing research on QOL in ACHD can be attributed to a lack of a clear
19 conceptual background, inconsistent methods and insufficient sample sizes [4]. Additionally, the high
20 heterogeneity of ACHD constitutes a substantial confounding factor due to their great anatomical and
21 clinical disease complexity. Most studies on QOL in ACHD focused on specific subgroups of patients
22 which limits their informational value. Consequently, clinical parameters were not sufficiently examined
23 to explain potential differences in QOL by the underlying diagnosis or severity of CHD. Although a
24 recent review attests temporal qualitative improvements in QOL studies over the last decades, the
25 current research situation still fails to meet scientific quality criteria [5].

26 The present study aimed to assess QOL within a large sample of ACHD in Germany and examine
27 potential determinants of QOL in terms of patient-related and medical characteristics. Identifying
28 determinants of QOL along with special needs of ACHD could advance the improvement of health care
29 for this growing patient population.

30 Methods

31 Design

32 The present study represents a sub-analysis of the nationwide VEMAH initiative (“Versorgungssituation
33 von Erwachsenen mit angeborenen Herzfehlern”, engl. “Medical Care Situation of ACHD”). Detailed

1 information on the rationale, design, and methods is documented in a former published paper
2 [6]. VEMAH is a multicenter, cross-sectional study to assess the health care situation of ACHD in
3 Germany. Coordination of VEMAH was initiated and carried out by the German Heart Center Munich.

4 Population

5 A questionnaire package was consecutively addressed to ACHD presenting at the Department of
6 Congenital Heart Disease and Pediatric Cardiology of the German Heart Center Munich and the
7 Department of Cardiology of the University of Erlangen. Additionally, the health insurance provider
8 “AOK Bayern” distributed questionnaires to their policyholders with CHD in Bavaria, and the “National
9 Register for Congenital Heart Defects” in Berlin, Germany, invited its members to participate in the
10 study online. Guidelines on good clinical practice and data protection guidelines were followed.
11 Inclusion criteria were: (1) confirmed diagnosis of CHD according to the definition of
12 Thiene & Frescura, [7] (2) participant age 18 years and older, (3) necessary physical, cognitive
13 and language capabilities to complete self-report questionnaires.

14 Measures

15 Patients completed a questionnaire either in person, online or by mail. Data collection took place
16 between 2016 and 2019. QOL was measured using the generic questionnaire EQ-5D-5L[8].

17 I. *Demographic and clinical information*

18 Sociodemographic and medical information was obtained by a self-devised questionnaire. Medical
19 variables included leading CHD, medication, presence of cyanosis, (non-) cardiac comorbidities and
20 hereditary diseases. Following the recommendations of the American College of Cardiology, patients
21 were divided into three severity groups based on their CHD diagnosis (ACC) [9].

22 II. *Quality of Life (EQ-5D-5L)*

23 QOL was measured using the updated five-level version of the EQ-5D [8] which provides a simple,
24 generic measure of a patient’s perceived health status. The EQ-5D-5L consists of a descriptive system
25 questionnaire and a visual analogue scale (VAS). The descriptive system comprises five dimensions:
26 mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each patient was asked to
27 indicate his perceived impairments on a 5-point Likert scale ranging from “no problems” to “extreme
28 problems/unable”. Responses were converted into a single weighted index score (EQ-5D index) which
29 indicates how good or poor the respondent’s health status is based on existing population norms. A value
30 set for the EQ-5D-5L, based on a representative sample of the German population, has recently been
31 developed [10]. The VAS indicates a patient’s overall health state on the day of the questionnaire
32 completion. It is a scale which ranges from 0 (“The worst health you can imagine”) to 100 (“The best
33 health you can imagine”) and provides a quantitative measure of a patient’s perceived health. The EQ-

1 5D-5L proved to be a reliable and valid method for measuring QOL in cardiovascular populations
2 (Cronbach's alpha = 0.856) [11].

3 Statistical analysis

4 Statistical analysis was performed using IBM SPSS Statistics 24.0 (IBM, Armond, New York, United
5 States). Descriptive measures were calculated for sample characteristics, including patient reported
6 sociodemographic and medical variables (absolute and relative frequencies, mean and standard
7 deviations). The relationships between CHD diagnosis groups and EQ-5D-index values, including the
8 underlying dimensions mobility, self-care, usual activities, pain/discomfort and anxiety/depression were
9 analysed. The comparison of ordinaly scaled values was based on cumulative frequencies representing
10 the relative proportion of patients with moderate to severe symptoms on the specific dimensions.
11 Kruskal-Wallis-tests were applied to reveal significant differences between EQ-5D-dimensions and
12 metric index values. Furthermore, the relationship between both EQ-5D VAS scores and dedicated index
13 values was analysed with respect to various patient characteristics. Multiple regression models using
14 Ordinary least squares (OLS)-estimates were calculated, while bivariate Pearson-coefficients were used
15 to analyse the correlation between VAS and index scores. Finally, multiple ordinal logit models were
16 applied to identify significant predictors of the respective QOL dimensions. For all tests, the
17 statistical significance level was set at $p < 0.05$. Data analysis was
18 currently performed for complete cases on each variable. To rule out
19 a potential distortion of findings, a further comparison between
20 statistically included and excluded patients was conducted and
21 revealed no significant differences concerning their QOL.

22 Patient and Public Involvement

23 Neither patients nor the public were involved in the design and conduct of this research. The
24 methodology of this research was adapted in multidisciplinary collaboration.

25 Results

26 Sample characteristics

27 A total of 4,014 patients was analysed (46.5% female) (**Table 1**). The mean age of ACHD was $41.8 \pm$
28 17.2 (18-97) years. Patients were subclassified according to the underlying CHD into six main groups,
29 consisting of complex CHD (n=581); pre-tricuspid shunts (n=621); post-tricuspid shunts (n=406); right
30 heart or pulmonary artery anomalies (n=526); left heart or aortic anomalies (n=898); and miscellaneous
31 CHD (n=602). 15.4 % of patients (n=602) presented with cyanosis. The severity of CHD was determined
32 according to the Warnes classification system as simple (n=1,722, 62.0%), intermediate (n=650, 23.4%)
33 or severe (n=406, 14.6%) [12].

1 QOL and ACHD

2 EQ-5D dimensions were found to be differently associated with CHD subgroups. Significant differences
3 between the underlying diagnosis were found on all dimensions ($p<.001$). Compared to all other
4 subgroups, pre-tricuspid shunts were particularly impaired in mobility, daily activities, pain/discomfort
5 and anxiety/depression (**Table 2**). In contrast, complex CHD showed the least problems on the respective
6 descriptive dimensions (**Figure 1-5**).

7 Similar results were reflected by EQ-5D VAS and index values ($p<.001$) with EQ-5D VAS values being
8 highest in patients with right heart/pulmonary artery anomalies and complex CHD and lowest in patients
9 with pre-tricuspid shunts. Observed differences were less extreme between descriptive EQ-5D index
10 values. Both EQ-5D values were positively correlated ($r=.623$, $p<.001$), with coefficients being the
11 lowest for patients with complex CHD ($r=.579$, $p<.001$) and highest for patients with left heart/aortic
12 anomalies ($r=.653$, $p<.001$). Variations in QOL were observed depending on the type of measurement
13 which was applied. Accordingly, the mean VAS score displayed a significantly lower QOL than the
14 descriptive EQ-5D index value.

15 Patient-related Determinants of QOL

16 OLS-Regression models were applied to analyse relationships of sociodemographic variables with EQ-
17 5D VAS and index values (**Table 3**). At the 5% level of significance, age had the highest negative impact
18 on VAS values ($\beta=-.32$) and Index values ($\beta=-.22$). Thus, QOL decreased with advancing age. Patients
19 aged 65+ years indicated the lowest values on both scales. Means for both EQ-values were slightly
20 higher in male than in female patients. Medication intake had significant negative effects on QOL in
21 both measures. Model fit was slightly higher for the dependent variable in VAS values ($R^2=.190$) than
22 EQ-5D index values ($R^2=.112$).

23 CHD-related Determinants of QOL

24 EQ-5D-dimensions were analysed more specifically in regard to different medical features such as
25 connective tissue disease diseases with cardiovascular involvement, cyanotic status and severity codes
26 of CHD. Several ordered logistic regression models were applied using each of the five dimensions as
27 dependent variables (**Table 4**). Generally, patients with comorbidities had significantly increased odds
28 of reporting problems on all dimensions than patients without comorbidities ($p<.05$). Non-cardiac
29 comorbidities accounted for significantly higher odds of having problems than cardiac comorbidities.
30 No significant effects could be observed for cyanotic status. Furthermore, regression models showed no
31 effects for patients with simple or moderate disease severity classes. Apparently, severely classified
32 patients indicated decreased odds of suffering from issues related to mobility or self-care than patients
33 in lower Warnes' classes.

1 Discussion

2 QOL is one of the most important measures used to assess the psychosocial impact of chronic disease
3 on a patient's life. This is the first study to investigate patient reported QOL within a cohort of 4,014
4 patients encompassing a broad spectrum of CHD. QOL in ACHD was assessed by utilizing the EQ-5D-
5 5L, a highly reliable and valid outcome measure within the cardiovascular area [13]. It comprises
6 two types of measurement and therefore provides a global view on QOL in terms of general life
7 satisfaction. This allowed to reveal genuine differences in QOL among patients with different medical
8 and sociodemographic backgrounds, regardless of methodological considerations. Within the context of
9 this study, QOL quantifies the influence of CHD on a patient's ability to function and derive personal
10 satisfaction from life.

11 QOL in ACHD

12 In line with previous findings [14], ACHD in general reported a good level of wellbeing which is
13 comparable to German population norms [15]. The two-fold measure of QOL revealed that the type of
14 measurement affects QOL scores differently. Apparently, the overall VAS score indicated a significantly
15 lower QOL than the descriptive EQ-5D index value. One explanation for this discrepancy are differences
16 in the QOL coverage of both measures. It can be assumed that the descriptive system encourages a
17 patient to examine QOL from various angles as the system breaks down QOL into various components.
18 Thus, QOL is regarded as a subjective concept being influenced by multiple causal factors [16]. In
19 contrast, VAS picks up a one-dimensional view of perceived health where patients may indicate a higher
20 occurrence of problems by focusing on somatic health restrictions imposed by their CHD. When
21 comparing the quantitative association of CHD with QOL to other chronic disorders, the average
22 reduction in VAS values in the current sample roughly resembles observations of various other heart
23 diseases [15]. In line with previous research, patients most frequently reported problems in the areas of
24 pain/discomfort (16.3%) and anxiety/depression (14.3%) [17]. These rates lie considerably above
25 German population standards, which document symptoms of anxiety/depression in 4.7% of the general
26 public. This result further supports previous research showing that ACHD are specifically prone to
27 increased psychological distress and therefore require additional psychosocial support [18].

28 A closer look at different diagnosis groups reveals, that patients with pre-tricuspid shunts were
29 particularly impaired in QOL. Comparable data have previously documented that QOL is not necessarily
30 congruent with the complexity or severity of a heart disease. Even mild primary pre-tricuspid shunts can
31 have a considerable negative impact on QOL [19]. Clinical reality shows that pre-tricuspid shunts are
32 often detected incidentally and later in life creating a different psychological situation than diagnosis of
33 CHD early in life. Children, who grew up with the awareness of their CHD, may acquire a greater sense
34 of appreciation for life and expectations consistent with their capabilities and limitations [20].
35 Qualitative research on ACHD indicates that patients perceive the awareness of their childhood
36 condition as a resource to re-evaluate life priorities and develop a new life perspective [21]. A recent

1 study has further established, that sense of coherence is a highly significant predictor of QOL in ACHD
2 [22]. Based on theoretical considerations, SOC develops during childhood and is thought to be fully
3 developed by the age of 30 years [23]. Patients who may be diagnosed later in life may have missed the
4 chance to develop and refine coping mechanisms and may therefore experience the effects of their CHD
5 more negatively leading to higher emotional distress. Life-stage variables, such as age at diagnosis or
6 years of survival, need to be further investigated as possible determinants of QOL.

7 Socioeconomic determinants of QOL

8 Despite good overall QOL, EQ-5D index and VAS values deteriorated with increasing age. This might
9 be explained by the uncertainty in disease prognosis manifesting itself in an increased sense of
10 vulnerability in this patient group [24]. Most patients with CHD are known to do well in the first decades
11 of life until they eventually develop unexpected age and disease-related comorbidities. This
12 development deserves special attention as the group of ACHD is expected to grow steadily in the future
13 [1].

14 In contrast to previous findings [14], the present study revealed modest gender-related differences in
15 QOL. Females were more likely to report poor QOL than males. These findings may be attributed to
16 psychosocial factors rather than gender per se [25]. In general, gender is found to influence health
17 expectations, health behaviours and perceived health outcomes [26]. Females may face a triple burden
18 shouldering family responsibility, professional ambition and demands of their chronic disease. Research
19 has demonstrated that females were less likely to return to work, more likely to decline psychological
20 counselling and more socially isolated than males [27]. It has also been argued that females were more
21 willing to disclose problems than males concerning their QOL, which may partly explain the difference
22 in their QOL [26]. Engelfriet et al. (2005) also showed that females with CHD were more often
23 symptomatic and presented functional impairments, despite a higher overall mortality in males over a
24 5-year period [28]. Gender disparities in patient-provider communication and dissatisfaction with health
25 care might be another reason for decreased QOL in females. They might have higher expectations and
26 a stronger demand for more participatory encounters with their healthcare providers [25]. Improved
27 recognition and understanding of these gender-specific differences and challenges among ACHD is vital
28 to improve their cardiovascular health over the long-term.

29 Reported medication intake was inversely associated with QOL in the present study This appears
30 plausible because extensive or inappropriate medication can lead to severe side effects and even higher
31 morbidity which may considerably impair QOL [29]. Aside from incorrect pharmaceutical treatment,
32 the daily intake of medication is a constant reminder of illness and may have a negative impact on life
33 satisfaction. Consequently, medication may either be a facilitator by providing new opportunities or an
34 intensifier of problems by adverse psychological and somatic side effects.

1 **Clinical determinants of QOL**

2 Despite all advances in cardiac care, many CHD patients are left with significant residual, sequelae or
3 complications from the underlying anomaly [9, 30]. The impact of comorbidities in ACHD is largely
4 underestimated [31]. The current study indicates that the presence of comorbidities increases the risk of
5 problems on all dimensions of the EQ-5D. It is conceivable that affected patients report a lower health
6 status since they may experience serious restrictions in various life domains. As comorbidities become
7 increasingly dominant with advancing age, they may also explain the recorded deterioration of QOL
8 with age in the present sample.

9 It is remarkable that patients with a more complex CHD scored significantly better in QOL domains.
10 Until now, research has failed to demonstrate a clear-cut correlation between disease complexity and
11 QOL [4]. Although the present finding may seem counterintuitive at first, there are various possible
12 explanations for a better QOL in the light of a chronic condition. Keyes' two continua model of mental
13 health [32] provides an important framework for explaining why patients might experience a good QOL
14 despite their CHD. Accordingly, mental health is a complex state resulting from an interplay of
15 environmental and psychological factors that have a profound influence on one's subjective wellbeing.
16 Keyes' model holds that mental health (sometimes referred to as mental wellbeing) and mental illness
17 are orthogonally related phenomena and not two endpoints of one single continuum. Although the
18 current state of research confirms elevated levels of mental illness among ACHD [18], this does not
19 necessarily imply impaired mental wellbeing or decreased QOL among these patients. Furthermore, the
20 disability paradox explains why individuals may perceive a high QOL despite serious limitations.
21 Accordingly, QOL depends upon finding a balance in life and maintaining harmonious social
22 relationships [33]. The characteristics associated with a severe CHD may potentially include favourable
23 and compromising factors and thus explain both extremes of QOL in ACHD. Lastly, growing up with a
24 CHD can lead to a so-called "response shift" in terms of redefining priorities in one's life [34]. It is
25 perceivable that patients develop different values from those of healthy persons in the face of a life-
26 threatening, chronic illness. In this context, Sprangers et. al (1999) proposed a theoretical model to
27 clarify and predict changes in QOL as a result of various dispositional characteristics, a patient's health
28 status and mechanisms to accommodate to these changes [35].

29 Despite the extensive power of the present study, current results should be interpreted with caution due
30 to certain limitations. The study was retrospective and cross-sectional in nature and does not allow to
31 disentangle any conclusions about the directionality of effects or the development of QOL over time.
32 Since all information was based on patient-reported outcomes, medical data may have been classified
33 incorrectly due to a patient's limited knowledge of his or her condition. Consequently, surgical status of
34 patients could not be identified. Subsequently, it would be advisable to synchronize these data with
35 medical records in order to disentangle the effects of empirical-medical observations on QOL. As the
36 enrolment was voluntary, selection bias could not be excluded and may hamper representativeness.
37 Further, this study was performed at a tertiary care center for ACHD which does not reflect the typical

1 population of CHD. Further doubts must be raised about whether the applied EQ-5D-5L provides an
2 accurate tool to evaluate QOL among AHCD. Although the updated 5L version demonstrates superior
3 performance compared to its predecessor, psychometric properties in terms of high ceiling effects and
4 weak discriminatory power have previously been questioned [36]. It has further been shown that the
5 choice of value set has an impact on EQ-5D scores [37]. Since the present study used a population-based
6 value set to construct QOL estimates, we strongly encourage to re-evaluate current findings on the basis
7 of experience-based value sets. Further, the inventory was administered in three different ways.
8 However, measurement invariance across the survey methods was not tested and the equivalence across
9 the survey methods remains questionable. Since the primary aim of this study was to assess clinical
10 determinants of QOL, sociodemographic variables were not explicitly reviewed within the present
11 analysis. Based on the German healthcare system, the depicted sociodemographic variables are crucial
12 indicators of access to medical supply and were therefore separately analyzed. Given previously
13 documented associations between sociodemographic factors and QOL, generalization of the conclusions
14 and transmission to patients from differing socioeconomic conditions is debatable. The present survey
15 assessed biological sex with a binary value. Given the increasing incidence of transgender and gender
16 non-binary individuals and that large health disparities exist for this population [38], future research
17 should increasingly expand measures of sex/gender to be trans inclusive. Finally, no control group was
18 involved, and data could only be compared to published national EQ-5D studies.

19 **Conclusion**

20 The present study shows that ACHD experience – on aggregate – a good QOL which is indistinguishable
21 from healthy individuals. Against expectation, patients with complex CHD scored higher on QOL.
22 However, specific subgroups of patients indicate significant reductions in QOL and may require extra
23 support in their care to cope with challenges associated with their underlying CHD. The negative
24 correlation with age deserves particular attention as it could lead to a decrease in QOL with the growing
25 median age of this patient population.

26 QOL is regarded as a central target in the treatment of chronically ill patients. This study supports the
27 need to further assess and promote mental wellbeing in ACHD to safeguard surgical successes of the
28 past decades which have ensured the survival of CHD patients into adulthood. Successful treatment
29 implies not only an increased length of survival but also enhanced subjective wellbeing and QOL.

30 **Declarations**

31 **Funding:** This work was supported by the German Heart Foundation (“Deutsche Herzstiftung e.V.”)
32 (grant number F-30-15), the patient organization “Herzkind e. V.”, Actelion Pharmaceuticals Germany
33 GmbH (grant number MED-2015-495) and the German health care insurance AOK-Bayern

1 **Competing Interest:** The authors have no conflicts of interest to declare.

2 **Ethics Approval:** The study was part of the nationwide VEMAH project which was approved on
3 04/05/2016 by the ethical committee of the Technical University of Munich (157/16S).

4 **Consent to participate:** Informed consent was obtained from all individual participants included in the
5 study.

6 **Consent for publication:** All authors consent to the publication of the manuscript in the Journal
7 “Clinical Research in Cardiology”.

8 **Availability of data and material:** The datasets generated during and/or analysed during the current
9 study are available from the corresponding author on reasonable request.

10 **Author Contributions:**

11 (1) *Conception and design:* CA, HK, JB

12 (2) *Administrative support:* CA, SF, SA, PE, UG, JH, HK, LP, MW, RN, JB

13 (3) *Collection and assembly of data:* CA, SF, SA, UG, MW

14 (4) *Data analysis and interpretation:* CA; SF

15 (5) *Manuscript writing:* CA, JB

16 (6) *Final approval of manuscript:* CA, SF, SA, PE, UG, JH, HK, LP, MW, RN, JB

17 .

1 References

1. Zimmerman MS, Smith AGC, Sable CA, Echko MM, Wilner LB, Olsen HE, et al. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Child Adolescent Health*. 2020;4(3):185-200.
2. Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. *J American heart journal*. 2005;150(2):193-201.
3. Hunter AL, Swan L. Quality of life in adults living with congenital heart disease: beyond morbidity and mortality. *Journal of thoracic disease*. 2016;8(12):E1632.
4. Moons P, Luyckx K. Quality-of-life research in adult patients with congenital heart disease: current status and the way forward. *J Acta Paediatrica*. 2019;108(10):1765-72.
5. Bratt E-L, Moons P. Forty years of quality-of-life research in congenital heart disease: Temporal trends in conceptual and methodological rigor. *International journal of cardiology*. 2015;195:1-6.
6. Neidenbach R, Achenbach S, Andonian C, Bauer UM, Ewert P, Freilinger S, et al. Systematic assessment of health care perception in adults with congenital heart disease in Germany. *Cardiovascular Diagnosis Therapy*. 2021.
7. Thiene G, Frescura C. Anatomical and pathophysiological classification of congenital heart disease. *Cardiovascular Pathology*. 2010;19(5):259-74.
8. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *J Quality of life research*. 2011;20(10):1727-36.
9. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2018:CIR. 0000000000000603.
10. Grochtdreis T, Dams J, König H-H, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. *J The European Journal of Health Economics*. 2019;20(6):933-44.
11. Boczor S, Daubmann A, Eisele M, Blozik E, Scherer M. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L™. *J BMC public health*. 2019;19(1):1464.
12. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI, et al. Task force 1: the changing profile of congenital heart disease in adult life. *Journal of the American College of Cardiology*. 2001;37(5):1170-5.
13. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. *Health quality of life outcomes*. 2010;8(1):13.
14. Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, et al. Quality of life of adults with congenital heart disease in 15 countries: evaluating country-specific characteristics. *Journal of the American College of Cardiology*. 2016;67(19):2237-45.
15. Huber MB, Reitmeir P, Vogelmann M, Leidl R. EQ-5D-5L in the general German population: comparison and evaluation of three yearly cross-section surveys. *International journal of environmental research public health*. 2016;13(3):343.
16. Moons P, Deyk KV, Bleser LD, Marquet K, Raes E, Geest SD, et al. Quality of life and health status in adults with congenital heart disease: a direct comparison with healthy counterparts. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2006;13(3):407-13.

17. Berghammer M, Karlsson J, Ekman I, Eriksson P, Dellborg M. Self-reported health status (EQ-5D) in adults with congenital heart disease. *J International journal of cardiology*. 2013;165(3):537-43.
18. Andonian C, Beckmann J, Biber S, Ewert P, Freilinger S, Kaemmerer H, et al. Current research status on the psychological situation of adults with congenital heart disease. *2018;8(6):799*.
19. Vigl M, Niggemeyer E, Hager A, Schwedler G, Kropf S, Bauer U. The importance of socio-demographic factors for the quality of life of adults with congenital heart disease. *Quality of Life Research*. 2011;20(2):169-77.
20. Moons P, Norekvål TM. Is sense of coherence a pathway for improving the quality of life of patients who grow up with chronic diseases? A hypothesis. *J European Journal of Cardiovascular Nursing*. 2006;5(1):16-20.
21. Moreland P, Santacroce SJ. Illness uncertainty and posttraumatic stress in young adults with congenital heart disease. *The Journal of cardiovascular nursing*. 2018;33(4):356.
22. Moons P, Apers S, Kovacs AH, Thomet C, Budts W, Enomoto J, et al. Sense of coherence in adults with congenital heart disease in 15 countries: Patient characteristics, cultural dimensions and quality of life. *European Journal of Cardiovascular Nursing*. 2021;20(1):48-55.
23. Antonovsky A. *Unraveling the mystery of health: How people manage stress and stay well*: Jossey-bass; 1987.
24. Saliba Z, Butera G, Bonnet D, Bonhoeffer P, Villain E, Kachaner J, et al. Quality of life and perceived health status in surviving adults with univentricular heart. *%J Heart*. 2001;86(1):69-73.
25. Chen C-A, Liao S-C, Wang J-K, Chang C-I, Chiu S, Chen Y-S, et al. Quality of life in adults with congenital heart disease: biopsychosocial determinants and sex-related differences. *Heart*. 2011;97(1):38-43.
26. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. *Journal of general internal medicine*. 2001;16(4):266-75.
27. Ford ES, Mokdad AH, Li C, McGuire LC, Strine TW, Okoro CA, et al. Gender differences in coronary heart disease and health-related quality of life: findings from 10 states from the 2004 behavioral risk factor surveillance system. *J Journal of Women's Health*. 2008;17(5):757-68.
28. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilén U, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period: the Euro Heart Survey on adult congenital heart disease. *J European heart journal*. 2005;26(21):2325-33.
29. Olsson IN, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. *J Health quality of life outcomes*. 2011;9(1):95.
30. Perloff JK, Warnes CA. Challenges posed by adults with repaired congenital heart disease. *Circulation*. 2001;103(21):2637-43.
31. Neidenbach RC, Lummert E, Vigl M, Zchoval R, Fischereder M, Engelhardt A, et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovascular Diagnosis and Therapy*. 2018.
32. Keyes CL. The mental health continuum: From languishing to flourishing in life. *J Journal of health social behavior*. 2002:207-22.
33. Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. *Social science & medicine*. 1999;48(8):977-88.
34. Rapkin BD, Schwartz CE. Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift. *Health and quality of life outcomes*. 2004;2(1):14.

- 1
2
3
4 1 35. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of
5 2 life research: a theoretical model. *J Social science medicine*. 1999;48(11):1507-15.
6 3 36. Feng Y, Parkin D, Devlin NJ. Assessing the performance of the EQ-VAS in the NHS
7 4 PROMs programme. *Quality of Life Research*. 2014;23(3):977-89.
8 5 37. Leidl R, Reitmeir P. An experience-based value set for the EQ-5D-5L in Germany.
9 6 *Value in Health*. 2017;20(8):1150-6.
10 7 38. Bauer GR, Braimoh J, Scheim AI, Dharma C. Transgender-inclusive measures of
11 8 sex/gender for population surveys: Mixed-methods evaluation and recommendations. *PloS*
12 9 *one*. 2017;12(5):e0178043.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Characteristics of the underlying study population.

Variables	n (%)
Age group (n=3,903)	
18-34	1,663 (42.6)
35-64	1,733 (44.4)
65+	507 (13.0)
Gender (n=3,898)	
male	2,087 (53.5)
female	1,811 (46.5)
Residence (n=3,855)	
City	775 (20.1)
Town	590 (15.3)
Rural	2,490 (64.6)
Insurance (n=3,905)	
Public	3,679 (94.2)
Private	219 (5.6)
No Insurance	7 (.2)
Type of CHD (n=4,014)	
Complex Congenital Heart Defects	581 (14.5)
Primary Pre-Tricuspid Shunts	621 (15.5)
Primary post-Tricuspid Shunts	406 (10.1)
Right Heart / Pulmonary artery anomalies	526 (13.1)
Left Heart / Aortic anomalies	898 (22.4)
Miscellaneous CHD	602 (15.0)
Unclassifiable	380 (9.5)
Warnes Class (n=2,778)	
Simple	1,722 (62.0)
Moderate	650 (23.4)
Severe	406 (14.6)

Table 2. Leading diagnosis of CHD and EQ-5D-results.

EQ-5D	Total	Complex Congenital Heart Defects	Primary pre- tricuspid shunts	Primary post- tricuspid shunts	Right Heart / pulmonary artery anomalies	Left Heart / aortic anomalies	Unclassifiable	Miscellaneous	p-Value
Dimension	n=4,014	n=581	n=621	n=406	n=526	n=898	n=380	n=602	
Mobility	12.2	8.6	13.6	10.4	9.6	10.5	15.0	16.6	<.001*
Self-Care	3.5	2.0	3.0	2.3	3.2	3.5	4.4	5.4	.017*
Usual activities	13.2	13.7	13.5	11.2	12.6	11.1	14.1	16.8	<.001*
Pain/Discomfort	16.3	13.7	20.4	12.3	11.8	14.3	19.5	22.7	<.001*
Anxiety/Depression	14.3	14.8	17.5	14.2	12.6	12.0	14.4	15.5	.002*
EQ-5D VAS	n=3,761	n=540	n=605	n=388	n=485	n=844	n=351	n=548	<.001*
Mean	76.15	78.21	73.29	77.28	79.50	77.36	74.32	72.80	
SD	18.97	17.12	19.93	19.90	17.48	18.55	19.56	19.57	
EQ-5D Index	n=3,690	n=540	n=583	n=383	n=489	n=828	n=344	n=523	<.001*
Mean	.90	.92	.89	.91	.92	.91	.88	.87	
SD	.15	.14	.15	.14	.15	.14	.16	.18	

Notes: Data for EQ-5D-dimensions represent relative percentages of patients, who indicated moderate to severe problems with respect to each dimension. Significant differences were calculated using Kruskal-Wallis-tests for independent samples.

Table 3. Patient characteristics and their correspondence with EQ-5D VAS and index values.

Variables	EQ-5D VAS				EQ-5D Index			
	Mean	SD	β	p	Mean	SD	β	p
Age group			-.32	<.001*			-.22	<.001*
18-34	83.46	14.75			.94	.11		
35-64	73.44	18.99			.89	.15		
65+	62.23	20.83			.82	.21		
Sex			.01	<.001*			.04	.004
Female	76.11	19.07			.90	.15		
Male	76.55	18.85			.91	.14		
Residence			.02	.084			.03	.060
City	76.30	17.49			.90	.15		
Town	77.08	18.26			.90	.15		
Rural	76.01	19.46			.90	.15		
Medication			-.22	<.001*			-.19	<.001*
No	79.16	17.13			.92	.13		
Yes	65.17	20.69			.83	.20		

Notes: Multivariate analysis was performed using OLS-regression models with EQ-5D VAS and Index values as dependent variables.

Table 4. Impact of medical features with respect to EQ-5D-dimensions.

Variable	n	Mobility n=3,070	Self- Care n=3,073	Usual activities n=3,068	Pain/discomfort n=3,051	Anxiety/depression n=3,061
Comorbidities						
Cardiac Comorbidities	1,463	.302* (.25-.36)	.525* (.38-.73)	.348* (.29-.41)	.331* (.28-.39)	.467* (.40-.54)
Non-Cardiac Comorbidities	819	.263* (.22-.32)	.281* (.20-.39)	.222* (.18-.27)	.311* (.26-.37)	.243* (.20-.29)
Cyanosis						
Cyanotic	744	.904 (.49-1.68)	.396 (.12-1.26)	.880 (.50-1.56)	1.088 (.65-1.82)	.850 (.51-1.41)
Acyanotic	2,176	1.452 (.70-3.02)	.774 (.20-3.04)	1.207 (.63-2.30)	1.011 (.58-1.77)	.695 (.40-1.19)
Warnes class						
Simple	1,722	1.396 (.69-2.84)	.707 (.18-2.84)	1.109 (.60-2.06)	.984 (.57-1.69)	.739 (.44-1.24)
Moderate	650	.848 (.50-1.45)	.538 (.17-1.69)	.985 (.60-1.61)	.884 (.57-1.37)	.921 (.60-1.41)
Severe	406	.384* (.19-.76)	.148* (.04-.58)	.710 (.39-1.30)	.620 (.36-1.08)	.742 (.43-1.27)

Notes: Displayed are odds ratios, upper and lower bounds (95% CI) respectively which were obtained from several ordered logistic regressions using EQ-dimensions as dependent variable.

* $p < .05$

1
2
3 **Figures**
4

5 **Figure 1: Distribution of scores for Mobility**
6

7 **Figure 2: Distribution of scores for Self-Care**
8

9 **Figure 3: Distribution of scores for Usual Activities**
10

11 **Figure 4: Distribution of scores for Pain/Discomfort**
12

13 **Figure 5: Distribution of scores for Anxiety/Depression**
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1: Distribution of scores for Mobility




Figure 2: Distribution of scores for Self-Care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Distribution of scores for Usual Activities




Figure 4: Distribution of scores for Pain/Discomfort

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5: Distribution of scores for Anxiety/Depression

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4/5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	4/5
		(b) Describe any methods used to examine subgroups and interactions	4/5
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5
		(b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	5-6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	n/a

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	5-6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	5-6
Discussion			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.